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Abstract
An impaired synaptogenesis is known to be a common neuropathology in a number of
severe mental disorders including schizophrenia, Parkinson disease, bipolar and
dementia. Protein tyrosine phosphatase 1B (PTP1B) has been reported to impair neurite
outgrowth and synaptic formation via attenuating Brain-derived neurotrophic factor
(BDNF)-mediated signalling. Leptin signalling also facilitates BDNF and promotes
synaptogenesis which is inhibited by PTP1B. Therefore PTP1B is a potential drug target
to reverse BDNF-mediated neurogenesis. In this study, lupane triterpenes, a cluster of
natural products, are determined as novel PTP1B allosteric inhibitors which inhibit
PTP1B with strong potency and selectivity. Lupane triterpenes inhibit psychotomimetic
drug-induced PTP1B and reverse PTP1B-caused BDNF reduction and neurogenesis
impairment, indicating that lupane triterpenes are potential drug candidates for PTP1B
inhibition and PTP1B-related neurological disorders.
Firstly, lupane triterpenes were identified as novel PTP1B allosteric inhibitors which
strongly and specifically inhibited PTP1B. In Chapter 2, through computational studies
including molecular docking and molecular dynamics simulations, lupane triterpenes
were confirmed to bind to PTP1B allosteric site. Following binding free energy
calculations were established to characterise the interactions between lupane triterpenes
structures and PTP1B allosteric binding site, providing evidence for future chemical
modifications. Moreover, pro-inflammatory factor TNFα stimulated PTP1B level in
neurons which was, however, inhibited by lupane triterpenes treatments. Considering
that PTP1B overexpression has been reported to impair BDNF-mediated neurogenesis
in neurons, it is of interest to investigate whether lupane triterpenes are able to reverse
PTP1B-mediated BDNF reduction and neurite outgrowth impairment in neurons.
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Secondly, PTP1B was found to be significantly increased in phencyclidine (PCP)treated neurons and caused downstream BDNF reduction and neurogenesis impairment.
In Chapter 3, the psychotomimetic drug PCP induced PTP1B through blockage of
NMDA receptor subunit 2B (NR2B). Enhanced PTP1B attenuated BDNF-mediated
Akt/GSK3β signalling, leading to reduced synaptogenesis. Furthermore, leptin increases
BDNF expression and promotes synaptogenesis which was also impaired by PCPinduced PTP1B. PTP1B directly inhibited JAK2 phosphorylation and thus attenuated
leptin signalling and pSTAT3, leading to reduced BDNF. Importantly, the study showed
that lupeol, one of the lupane triterpenes, significantly reduced PTP1B expression and
stimulated BDNF level, restored leptin signalling, BDNF-mediated signalling and
synaptogenesis. Lupeol also improved the treatment effects of current antipsychotic
drugs on reversing PCP-induced BDNF alterations, implicating PTP1B inhibition as a
potential treatment strategy.
Furthermore, I developed a label-free and high-throughput microfluidic platform based
on the inertial microfluidic technique to separate neurons and glial cells from dissected
brain tissue rapidly and continuously (see Chapter 4). The collected neurons and glia
were confirmed healthy with significantly improved purity. Moreover, PCP reduced
BDNF level in both separated and unseparated neurons with no significant difference,
indicating that the device did not change the cell biological properties responding to
drug treatment. Increasing evidence has shown that neurons and glia both play
significant roles in the development of neurite outgrowth and synaptic formation.
Therefore, it will be necessary to investigate the protein alterations, such as PTP1B, in
both cell types contributing to disease-induced impairment in neurogenesis and
synaptogenesis. However, it is difficult to differentiate the roles of neurons and glia
because the methods used to separate and collect neurons and glial cells from brain
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tissues are ineffective and inefficient. This microfluidic microchip can enrich and purify
both neurons and glia with unaltered morphology and biological function. We therefore
anticipate that this microfluidic device will be an outstanding platform for future cell
culture studies to investigate disease mechanism and perform drug screening.
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Chapter One
1.1 Introduction
Protein Tyrosine Phosphatase 1B (PTP1B) is an intracellular protein which is widely
expressed in the human body including the brain, liver, muscles, and adipose tissue.
PTP1B has been found up-regulated in obesity, type 2 diabetes and breast cancer,
indicating PTP1B is a potential drug target in these diseases (Ukkola and Santaniemi,
2002, Zabolotny et al., 2008, Yip et al., 2010). Recent studies have revealed a new
aspect of PTP1B which inhibits BDNF/TrkB signalling and leads to impaired neurite
outgrowth and synaptic formation, implicating PTP1B as a therapeutic target in
neurological disorders (Ozek et al., 2014, Krishnan et al., 2015). It is therefore
necessary to develop PTP1B inhibitors. PTP1B traditional inhibitor is designed to target
PTP1B active site. It is difficult to achieve inhibition selectivity against PTB1B,
however, due to the fact that PTP1B active site and surrounding catalytic domains are
highly similar to other members of the Protein Tyrosine Phosphatase (PTP) family
(Julien et al., 2011, St-Pierre and Tremblay, 2012). PTP1B allosteric inhibitor was then
discovered and proposed as an alternative drug design strategy to specifically inhibit
PTP1B (Wiesmann et al., 2004, Zhang and Zhang, 2007). Therefore it is of interest to
develop novel PTP1B allosteric inhibitors and investigate their treatment efficacy.
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1.2 Literature Review
1.2.1 PTP1B is a recognized drug target for leptin resistance
Protein tyrosine phosphatase 1B is encoded by gene PTPN1 which is located on human
chromosome 20q13 (Brown-Shimer et al., 1990), a region identified as closely related
to obesity (Lembertas et al., 1997, Lee et al., 1999). Numerous epidemiological studies
have reported PTPN1 single nucleotide polymorphisms (SNPs) associated with
development of obesity in the worldwide population (Tsou and Bence, 2012). PTP1B is
ubiquitously expressed in the central nervous system (CNS) (Bence et al., 2006) which
is known to induce obesity via attenuating leptin signalling (Zabolotny et al., 2002).
Leptin is a hormonal signal which acts in the brain and controls food intake and energy
expenditure (Schwartz and Porte, 2005, Morton and Schwartz, 2011). The leptin
signalling pathway is initialized by the tyrosine phosphorylation of Janus Kinase 2
(JAK2) which subsequently modulates downstream signals such as the signal transducer
and activator of transcription 3 (STAT3) (Morris and Rui, 2009) (Fig.1.1). The
JAK2/STAT3 pathway is strongly linked to significant weight loss and feeding
inhibitions (Coppari et al., 2009). Phosphorylated STAT3 transports into cell nucleus
and affects regulation of appetite by affecting the transcription of hypothalamic
neuropeptides such as neuropeptide Y (NPY), agouti-related protein (AgRP) and
precursor pro-opiomelanocortin (POMC). NPY and AgRP stimulate food intake and
decrease energy expenditure as orexigenic factors which are opposite to anorexigenic
neuropeptide POMC (Schwartz et al., 2000) (Fig.1.1).
Leptin resistance in the CNS is one of the factors causing obesity. One of the
contributors to leptin resistance is PTP1B which dephosphorylates JAK2 and thus
attenuates central leptin signalling (Cheng et al., 2002) (Fig.1.1). Previous studies have
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revealed that pro-inflammatory factor TNF-α stimulates PTP1B via activating Nuclear
factor-κB (NF-κB), leading to leptin resistance (Picardi et al., 2010, Yu et al., 2013a)
(Fig.1.1). Inhibition of neuronal PTP1B is essential to maintain leptin sensitivity as well
as prevent obesity development (Bence et al., 2006). Neuron-specific deletion of PTP1B
in mice has shown lower adiposity, enhanced leptin sensitivity, improved energy
expenditure and has prevented weight gain in animals fed a high-fat diet (Bence et al.,
2006). Moreover, central administration of PTP1B antisense oligonucleotides also
displays reduced hypothalamic PTP1B expression in a diet-induced obese (DIO) rat
model, resulting in restored leptin signalling and control of energy balance (Picardi et
al., 2010). Therefore PTP1B is a drug target for obesity treatment.
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Figure. 1.1: PTP1B attenuates leptin signalling via blocking the JAK2/STAT3 pathway
and leads to development of obesity. Leptin signalling is activated via JAK2
phosphorylation which further regulates pSTAT3 and downstream gene transcription
including POMC, AgRP and NPY to modulate energy homeostasis. Furthermore,
PTP1B inhibits BDNF receptor TrkB phosphorylation and therefore attenuates BDNFmediated Akt/GSK3β signalling, leading to impaired neurite outgrowth and
synaptogenesis. TNF-α is a critical pro-inflammatory cytokine activation of NF-κB
which results in over expression of PTP1B.
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1.2.2 New aspect of PTP1B: a BDNF signalling blocker in neurological disorders
As already mentioned, PTP1B has been demonstrated to attenuate leptin signalling
(Zabolotny et al., 2002). Leptin is not only beneficial to energy homeostasis but also
plays an important role in promoting synaptogenesis and neurite outgrowth to facilitate
learning and memory (Bariohay et al., 2005, Komori et al., 2006, Yamada et al., 2011).
One of previous study has reported that leptin stimulation improves neurite outgrowth
and synaptogenesis markers in mouse neural cell lines, as well as increasing cell
proliferation and differentiation to promote hippocampal neurogenesis (Moon et al.,
2013). In in vivo studies, memory deficits and decreased synapse density have been
observed in leptin or leptin receptor deficient rodents (Li et al., 2002, Bouret et al., 2004,
Pinto et al., 2004, Farr et al., 2006), such as ob/ob mice, db/db mice and fa/fa rats.
Importantly, leptin administration increases brain-derived neurotrophic factor (BDNF)
mRNA in the hypothalamic nucleus and facilitates BDNF expression in hypothalamic
STAT3-positive neurons (Komori et al., 2006). Numerous studies have revealed that
BDNF plays an important role in regulating neurite outgrowth, synaptic plasticity and
cognitive function (Huang and Reichardt, 2001).
BDNF and its receptor, tropomyosin-related kinase B (TrkB) are highly expressed in a
number of brain regions. BDNF has a high affinity to bind TrkB receptor on either side
of the synapse, facilitating both presynaptic release of excitatory neurotransmitters and
postsynaptic receptor insertion, as well as spine maintenance (Noble et al., 2011).
Recently, Ozek et al. reported that PTP1B overexpression inhibited BDNF/TrkB
signalling while inhibition of PTP1B or genetic PTP1B deficiency restored BDNF/TrkB
signalling and BDNF-mediated neurite outgrowth and BDNF-induced metabolic effects
(Ozek et al., 2014). Krishnan et al. further demonstrated that PTP1B inhibited tyrosine
phosphorylation of TrkB to attenuate BDNF signalling in the neurological disorder Rett
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syndrome model which presents autistic features (Fig.1.1). Pharmacological inhibition
of PTP1B ameliorated the behaviour test and improved survival in mice models
(Krishnan et al., 2015). Increasingly, studies have disclosed the influence of PTP1B on
neuronal development. Fuentes et al. revealed that PTP1B participated in neuronal
plasticity formation and reduction of PTP1B level improved dendritic filopodia,
learning and memory (Fuentes et al., 2012). It is important to note that the reduction of
BDNF has been reported in a number of mental disorders including schizophrenia
(Angelucci et al., 2005, Favalli et al., 2012). Therefore it is of great interest to
investigate the role of PTP1B in modulating BDNF-mediated neurite outgrowth and
synaptogenesis in schizophrenia-like models.
1.2.3

Phencyclidine

models

show

BDNF reduction

and

dysfunction

in

schizophrenia
Phencyclidine (PCP) is a recognized psychotomimetic drug. PCP is a non-competitive
and dosage-dependent blocker of the N-methyl-D-aspartate (NMDA)-type glutamate
receptors, binds equally to NMDA receptor subunit 2A (NR2A) and NMDA receptor
subunit 2B (NR2B) (Paoletti and Neyton, 2007) and induces psychotic symptoms that
are similar to schizophrenia in humans and rodents (Javitt and Zukin, 1991, Morris et al.,
2005). Apart from other recognized psychotomimetic drugs including amphetamine,
PCP is capable of mimicking negative symptoms such as alogia, anhedonia, and social
withdrawal, as well as cognitive deficits in addition to positive symptoms including
delusions, hallucinations, and thought disorder in schizophrenia (Andreasen, 1995,
Jentsch and Roth, 1999). PCP has been reported to induce reduction of neurite
outgrowth and synaptogenesis. The effects of PCP on reducing dendritic spine density
and neurite outgrowth have been reported in both in vitro and in vivo studies (Hajszan et
al., 2006, Adachi et al., 2013). A decreased number of spines in the prefrontal cortex of
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rats has been confirmed using sub-chronic PCP treatment (Hajszan et al., 2006),
suggesting that PCP treatment contributes to abnormal synaptic function in
schizophrenia-related behaviours (Frankle et al., 2003).
BDNF alteration is widely observed in schizophrenia pathophysiology (Favalli et al.,
2012). Durany et al. observed reduced concentration of BDNF in post-mortem tissue
collected from patients with schizophrenia, compared to control (Durany et al., 2001).
Increasing evidence also shows the alteration of BDNF transcriptional level. Weickert et
al. found a significant decrease of BDNF mRNA, TrkB mRNA and BDNF level in
schizophrenia patients (Weickert et al., 2003, Weickert et al., 2005). The majority of
studies have found the reduction of BDNF serum level in first-episode and medication
naive schizophrenia patients compared to healthy control (Buckley et al., 2007, Chen et
al., 2009).
Previous studies have reported that PCP treatment is associated with alteration of BDNF
protein level and mRNA level. Sub-chronic PCP administration induced severe
disruption of cognitive performance with reduction of BDNF in various regions of rat
brains (Snigdha et al., 2011). Other researchers have administered PCP in cultured
cortical neurons and disclosed decreased BDNF mRNA level (Katanuma et al., 2014).
A recent study found that PCP treatment for 48 hours reduced the amount of BDNF,
decreased secretion of BDNF and inactivated Trk receptors in cultured neurons. The
number of synaptic sites and expression of synaptic proteins were also suppressed,
together with diminished glutamatergic neurotransmission (Adachi et al., 2013).
Moreover, PCP suppressed the BDNF-mediated signalling Akt/GSK3β pathway
(Adachi et al., 2013), which has been shown to regulate synaptogenesis and neurite
outgrowth (Kitagishi et al., 2012, Smillie et al., 2013) (Fig.1.1). For example, Akt
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facilitated dendritic spine protein and Akt phosphorylation involved in working memory
formation (Emamian et al., 2004). GSK3β was expressed abundantly in neurons in the
developing rat brain to regulate dendrite extension and synapse formation (Leroy and
Brion, 1999). Therefore, BDNF reduction and dysfunction are responsible for the loss
of synaptic connections caused by PCP. Since PTP1B inhibits BDNF-mediated
signalling, it is interesting to investigate the role of PTP1B in PCP models and develop
potent PTP1B inhibitors to reverse PCP induced alterations.
1.2.4 Neuregulin-1 (NRG1) and susceptibility to schizophrenia
A genome-wide scan of diverse schizophrenia populations has provided insight into
mechanisms of this disorder and revealed several genes, such as neuregulin-1(NRG1),
to be closely associated with schizophrenia (Stefansson et al., 2002, Harrison and
Weinberger, 2004). Research on NRG1 and its receptor ErbB4 (v-erb-a erythroblastic
leukaemia viral oncogene homolog 4) improved our understanding of schizophreniainduced impairment of neurodevelopment, neurotransmission and synaptic plasticity
(Mei and Xiong, 2008). It has been reported that mutant mice, heterozygous for either
NRG1 or ErbB4, displayed behaviour abnormality, cognitive deficit and reduced
functional NMDA receptors compared to wild-type mice, which however overlapped
with mouse models for schizophrenia (Stefansson et al., 2002). Therefore models based
on NRG1 mutation have been established to explore the implications for the
pathophysiology of schizophrenia and potential treatments.
Recent studies have used NRG1-/+ mutant mice to investigate the interactions between
NRG1 and NMDA receptor (Bjarnadottir et al., 2007, Zhang et al., 2016). NRG1
signalling has been confirmed to stimulate phosphorylation of Y1472 on the NR2B
subunit of the NMDA receptor which played a key role regulating channel properties.
The reduction of NR2B Y1472 phosphorylation was associated with the behavioural
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abnormalities and altered synaptic plasticity in NRG1 -/+ mutant mice. These results
indicated that attenuated NRG1/ErbB4 signalling contributed to the psychopathology of
schizophrenia through the impairment of NMDAR modulation, NR2B in particular.
1.2.5 Challenges in discovering PTP1B traditional inhibitors: disadvantages of
targeting PTP1B active site
Full-length PTP1B (encoded by PTPN1) is 435 amino acids (about 50 kDa) (Chernoff
et al., 1990), including an N-terminal catalytic domain (the so-called PTP domain) and a
C-terminal domain which localizes the PTP1B to the endoplasmic reticulum (Frangioni
et al., 1992) (Fig.1.2a). PTP1B belongs to the Protein Tyrosine Phosphatases (PTPs)
family, which contains more than 100 members. Most members display a consensus
catalytic loop signature (H/V)C(X)5R(S/T), the so-called PTP loop or catalytic loop,
which is normally composed of 8 amino acids from His214 to Arg221 (Barford et al.,
1994), including the active site Cys215 which is conserved and essential for enzyme
catalysis (Julien et al., 2011, St-Pierre and Tremblay, 2012). PTP1B also contains a PTP
loop located in a catalytic cleft formed by four other loops. The depth of the catalytic
cleft contributes to specifically recognizing tyrosine as the substrate (Johnson et al.,
2002).
As previously mentioned, the PTPs family has many members. One of them is T-cell
protein tyrosine phosphatase (TCPTP) which is similar in structure to PTP1B. TCPTP
(encoded by PTPN2) is cloned from a peripheral human T-cell cDNA library (Cool et
al., 1989). The alternative splicing gives rise to two variants of TCPTP (Fig.1.2a): a 45
kDa form (TC45) which lacks the hydrophobic C-terminus and targets the nucleus, and
a 48kDa form (TC48) which localizes to the Endoplasmic reticulum (ER) by the Cterminus (Tiganis et al., 1999, Tiganis and Bennett, 2007). The amino acid sequence
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identity between the PTP domains of TCPTP and PTP1B is 74% (Fig.1.2a) with a
minor difference in four clusters of amino acid residues, and TCPTP shares a strong
similarity with PTP1B in 3D structure (Fig.1.2b). Additionally, TCPTP has a catalytic
cleft containing the active site Cys216 and the catalytic efficiencies between TCPTP
and PTP1B are almost identical based on their catalytic constant (Kcat) and Michaelis
constant (Km) (Iversen et al., 2002). However TCPTP regulates different biological
functions despite high structural similarity to PTP1B. PTP1B has been confirmed to
dephosphorylate JAK2 to attenuate leptin signalling while TCPTP dephosphorylated
JAK1 and JAK3 to regulate the immune system (Simoncic et al., 2002), suggesting that
TCPTP may have little influence on mediating central leptin signalling. In an addition,
entirely TCPTP knock-out mice showed damage in their immune system such as
haematopoiesis defects (You-Ten et al., 1997).
The active site plays as an essential role in PTP1B catalysis which processes as a twostep mechanism. In the first step, the sulphur atom of Cys215 begins a nucleophilic
attack on the phosphate on the tyrosine, and then Asp181 acts as a general acid to
protonate the tyrosyl-leaving group of the substrate. An intermediate cysteinylphosphate is therefore formed (Tonks, 2003). In the second step, the phosphate is
released from the intermediate by hydrolysis, mediated by Gln262 and Asp181.
Traditional PTP1B inhibitor design targets the active site Cys215 and most active-site
targeted inhibitors are non-hydrolyzable pTyr mimetics (Zhang and Zhang, 2007). The
traditional inhibitors target both active site residues and neighbouring residues, so called
subpockets which are adjacent to the PTP active site to increase the inhibition
selectivity (Zhang, 2002). However considering PTP1B and TCPTP share a very similar
active site loop and surrounding loops (Iversen et al., 2002), it is doubtful whether the
selectivity of active-site targeted drugs, PTP1B traditional inhibitors in other words,
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inhibit PTP1B over TCPTP. On the other hand, PTP1B traditional inhibitors are pTyr
mimetics which generally display high charge density, making it difficult to penetrate
cell membranes, leading to poor bioavailability. Therefore, the novel drug discovery is
targeting the allosteric site of PTP1B which inhibits PTP1B activity by affecting the
movement of WPD (Residues 179-181, Trp-Pro-Asp) loop in PTP1B (Wiesmann et al.,
2004).
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Figure. 1.2: This picture represents the strong similarity of structure in the PTP domain
between TCPTP and PTP1B. They have 74% identity in sequence (a) and strong
similarity in the 3D structure (b). Due to the conservative catalytic domains, it is
difficult to develop selective PTP1B inhibitors which specifically target PTP1B (PDB
code: 1PTY) over TCPTP (PDB code: 1L8K).
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1.2.6 Developing PTP1B allosteric inhibitors is an alternative strategy
The WPD (Residues 179-181, Trp-Pro-Asp) loop is an important feature in the catalysis
of PTP1B (Barr, 2010). Under physiological conditions, protein can exhibit multiple
conformations and sometimes involve large-scale conformational transitions (so-called
allosteric transition) in contrast to the usual static view brought by a single structure.
This is nicely illustrated by the movement of the WPD loop in PTP1B captured by Xray crystallography. During the transition of the WPD loop in catalysis, PTP1B
expresses two different conformations, open and closed (Fig.1.3c). In the open model
(PDB Entry 2HNP), the WPD loop forms an open binding crevice which allows active
site access to reach the tyrosine substrate and in the closed conformation (PDB Entry
1SUG), the WPD loop closes over the cleft where the active site forms an intermediate
with the phosphate, sequestering the cysteinyl-phosphate intermediate and one
nucleophilic water molecule (Pannifer et al., 1998), finally, phosphoryl transfer from the
intermediate to the buried water molecular occurs and the WPD loop re-opens the cleft
to continue catalysis. The conformation difference provides a new design of PTP1B
inhibitors called PTP1B allosteric inhibitors. Allosteric inhibition aims to prevent WPD
movement from open mode to closed mode and results in the inactivity of PTP1B. In
2004, the PTP1B allosteric site was identified, sited 20 Å away from the catalytic pocket
(Wiesmann et al., 2004) (Fig.1.3a). The high-resolution crystal structures of PTP1B in
complex with allosteric inhibitors including compound 2 and compound 3 (Fig.1.4),
revealed that instead of targeting the enzymatic active site, these inhibitors bond to an
allosteric site composed by 3, 6 and 7 (Wiesmann et al., 2004) (Fig.1.3b). It has
been proposed that through long-range coupling these allosteric inhibitors can prevent
the closure of the WPD loop and thus the formation of the active state of the enzyme. In
this way, the inhibitors locked PTP1B in a catalytically incompetent state. It is
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encouraging that the allosteric inhibitors showed high potency in inhibiting PTP1B
while at the same time having significant selectivity over TCPTP. Allosteric inhibitors
have advantage over other inhibitors, which target the active site, since key residues
involved in the allosteric binding are not conserved in most PTPs (Zhang and Zhang,
2007). Interestingly, this allosteric inhibition strategy has also been applied to target
SHP2, which is another member of the PTPs family, showing a potent, selective and
orally efficacious inhibition (Chen et al., 2016, Garcia Fortanet et al., 2016). Therefore,
allosteric inhibition is an ideal treatment strategy in PTPs inhibition including PTP1B.
Considering only a few selective PTP1B inhibitors with acceptable pharmacological
properties are under clinical trials, such as TransTech Pharma Inc TTP814, and Ohr
Pharmaceutical Inc Trodusquemine (MSI-1436) (Krishnan et al., 2014), which are in
Phase II and Phase I testing, respectively (Osherovich, 2011), it is necessary to develop
novel PTP1B allosteric inhibitors.
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Figure. 1.3: The crystallography structure of PTP1B. PTP1B has an active site Cysteine
215 with surrounding catalytic loop (a) and an identified allosteric site (b) which is
surrounded by the α3 helix, α6 helix and α7 helix. During PTP1B activation, the WPD
loop (c) moves from the open position to the closed position. Allosteric inhibition aims
to prevent the WPD loop to keep PTP1B in an inactive state and lose activity.
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1.2.7 Lupane triterpenes are candidates as PTP1B allosteric inhibitors
Triterpenes are pentacyclic chemical compounds which are major natural components
of human diets, isolated from vegetable oils, cereals and fruits (Moreau et al., 2002).
Previous studies have mentioned the enormous utility of triterpenes as anti-cancer drugs,
anti-inflammation drugs and anti-diabetes drugs (Ovesna et al., 2004, Liby et al., 2007).
As one family of triterpenes, lupane triterpenes have been studied for decades. Lupane
triterpenes are major natural components of vegetables, fruits and medical plants
including white cabbage, pepper, carrot, pea, birch bark, rosemary leaves and mistletoe
shoots (Laszczyk, 2009). Previous studies have established lupane triterpenes as anticancer drugs, anti-inflammation drugs, anti-diabetes drugs and anti-viral drugs (Baltina
et al., 2003, Tolstikova et al., 2006). Lupane triterpenes have four members including
lupeol, lupenone, betulin and betulinic acid (Fig.1.4). All four members of lupane
triterpenes have shown potent PTP1B inhibition activity in vitro (Na et al., 2009, Choi
et al., 2009, Xu et al., 2009). One previous study has shown that lupeol could inhibit
PTP1B with a high potency (IC50=5.6M) (Na et al., 2009) and the extra kinetic assay
indicates that lupeol acts as a non-competitive inhibitor of PTP1B which means lupeol
is a potential PTP1B allosteric inhibitor. This is because when a compound inhibits the
enzyme, it could target on either active site as a competitive inhibitor or bind to
allosteric site as a non-competitive inhibitor. Lupeol fits in non-competitive inhibition
mode. Therefore lupeol is a potential PTP1B allosteric inhibitor. However, the
molecular mechanism and the location of the binding site of lupeol and other lupane
triterpenes targeting PTP1B remains speculative. Considering the promising results for
the allosteric PTP1B inhibitors, my work aims at characterising the selectivity and
binding mode of lupane triterpenes targeting PTP1B including lupeol, lupenone, betulin
and betulinic acid in silico and in vitro, as well as validating their biological and
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physiological functions in various cellular models, in order to develop ideal potential
PTP1B allosteric inhibitors in the future.

Figure .1.4: The formula of allosteric ligands used in this study. Compound 2 and 3
have been reported to be allosteric inhibitors by Wiesmann et al (Wiesmann et al., 2004).
Four members of lupane triterpenes were selected. It appears that lupeol, lupenone,
betulin and betulinic acid share a pentacyclic hydrophobic main structure with
distinctions of functional groups in the R1 and R2 positions.
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1.2.8 Application of computational modelling to determine lupane triterpenes as
PTP1B allosteric inhibitors
The present PhD project applies computational modelling as a method to characterise
the structural interactions between PTP1B and lupane triterpenes, to demonstrate lupane
triterpenes as PTP1B allosteric inhibitors. Computer-aided drug discovery plays a
critical role in the investigation of therapeutically small molecules to develop drug
candidates (Kubinyi, 2006). As a well-established computational technique, molecular
docking is applied to predict the preferred orientation of one molecular bond to another
(Kitchen et al., 2004), such as lupane triterpene to PTP1B. The interactions between two
molecules are mainly forces including electrostatic forces, van der Waal interactions
and solvent-related forces. All the types of energy will be detected by a search
algorithm and then converted into numerical values via a statistical scoring function.
Docking scores will be provided after the calculation which could help to evaluate the
most possible binding site of the molecule targeting the protein (Warren et al., 2006).
The relation between biological molecules always plays an important role in signal
transduction. By using docking to mimic the interaction between two molecules such as
lupane triterpene and PTP1B, could provide the information including affinity and
activity of the lupane triterpenes. However, docking only provides a rigid structure of
protein-ligand complex which is flexible in nature solvent environment (Kitchen et al.,
2004). Instead, molecular dynamics (MD) simulation is then applied to determine the
motion of atoms and resulting conformational change of lupane triterpenes upon
binding to PTP1B. MD calculates a time-dependent trajectory concerning the
movements of individual particles in a protein-ligand complex, to investigate the
stability and flexibility of the formed complex, and implicate the important structural
feature of the ligand and protein binding site involved in forming the bound complex
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(van Gunsteren et al., 2006). Overall, application of computational modelling aims to
disclose the binding mode of lupane triterpenes targeting PTP1B allosteric site, and
reveal the potential drug design strategy to improve efficacy.
1.2.9 Application of inertial microfluidic platform to separate and collect neurons
and glial cells
A cell culture model will be broadly applied in this project including primary neuron
culture, which is a widely used experimental method, closely mimicking the
physiological status of neurons in vivo and provides a convincing and convenient
platform to perform drug treatments. However one major challenge is to separate
neurons from complex cell mixtures dissected from brain tissues with high purity and
efficiency. For example, glial cell is the major component in brain tissue which
normally outnumbers neurons in mammalian brain regions (Bear MF, 2006). Mediumbased procedure is a conventional method for pure neuron and pure glial cell cultures
where NeuroBasal medium with FDU (5-Fluoro-2′-deoxyuridine) is used to inhibit glial
cells proliferation (Brewer, 1997, Hilgenberg and Smith, 2007, Medicine, 2015).
However, such a method requires long-term incubation with chemical treatment,
wasting both time and experimental materials. Apart from this medium-based separation
method, immune-specific separation is broadly applied in neuron-related research.
Fluorescence-activated cell sorting (FACS) and magnetically-activated cell sorting
(MACS) have been widely used for separating cells (Radbruch and Recktenwald, 1995).
However, labelling target cells with antibodies may disturb the immunochemistry
analysis on targets of interest. Therefore, a label-free and high-throughput technique is
required to continuously separate neurons and glial cells to bridge this gap for
neuroscience research. On the other hand, there is increasing evidence of glia, in
particular astrocyte abnormality, modulating synaptic dysfunction in several brain
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disorders including schizophrenia (Seifert et al., 2006, Allen, 2014). A recent study
observed that astrocyte loss in the prefrontal cortex triggered neuronal damage causing
cognitive impairment in the animal model (Lima et al., 2014). Therefore it is of great
interest to investigate the specific role of neurons and glia in in vitro schizophrenia-like
models in future studies. Furthermore, PTP1B has been recently found expressed in
microglial cells (Song et al., 2016), indicating the need for investigation of glial PTP1B
contributing to BDNF reduction in the future.
In the present study, I collaborated with a research group in the department of
engineering in University of Wollongong, to develop an inertial microfluidic device to
separate neurons and glial cells. This inertial microfluidic platform has a built-in
serpentine micro-channel made by Polydimethylsiloxane (PDMS), a bio-compatible
material, utilizing hydrodynamic forces to continuously separate particles of different
sizes with high performance (Zhang et al., 2014b) (Fig.1.5). Inertial microfluidics is a
very promising candidate due to its high throughput and simple structure, it has been
widely used to extract blood plasma (Lee et al., 2011, Zhang et al., 2014a), isolate
circulating tumour cells (CTCs) (Mach et al., 2011, Hou et al., 2013, Ozkumur et al.,
2013), and separate leukocytes from blood, (Wu et al., 2012) etc. As a label-free
technique without the use of antibody affinity, filter or centrifugation, inertial
microfluidics is highly desirable to ensure minimal damage and alteration to neurons.
This microfluidic device will be very useful to separate and collect both neurons and
glia spontaneously from the brain section of interest, and establish a platform to
characterise the specific role of neuron and glia in neurological disorders.
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Figure. 1.5: a): The inertial microfluidic device applied in this work. B): Schematic
illustration of the micro-channel structure used for cell separation. A filter upstream of
the serpentine channel prevents the channel from being blocked by large debris. A
trifurcation outlet system was used with middle outlet #1 for neuron collection, two
symmetrical side branches merged together as outlet #2 for glial cell collection.
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1.3 Aims
The aims of this research were to:
1. Determine lupeol and other lupane triterpenes as PTP1B allosteric inhibitors using
computational modelling and biological assay, to confirm these compounds specifically
bind to PTP1B allosteric site and selectively and potently inhibit PTP1B.
2. Investigate the role of PTP1B regulating BDNF level, BDNF-mediated signalling,
leptin signalling, synaptogenesis and neurite outgrowth in the PCP-mimicked
schizophrenia model and Neureglin-1 knockout animal model.
3. Demonstrate that lupane triterpene treatment is an effective treatment to alter PCPinduced BDNF reduction and neurogenesis impairment, indicating that PTP1B
inhibition is a potential therapeutic strategy to be combined with current antipsychotic
olanzapine to enhance treatment efficacy.
4. Develop an innovative microfluidic device to separate neurons and glial cells with
purity and viability, in order to provide a reliable platform to investigate the specific
role of neurons and glia in neurological diseases such as schizophrenia and associated
metabolic disorders.
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1.4 Hypothesis
1. Lupeol and other lupane triterpenes are PTP1B allosteric inhibitors which target
PTP1B allosteric site and form a stable protein-ligand complex. The structure of lupane
triterpenes will be characterised to provide advice for future chemical modifications.
Lupane triterpenes are able to specifically inhibit PTP1B over TCPTP, which will be
examined in this part of study.
2. PTP1B is significantly altered in Phencyclidine-treated and Neureglin-1 knockout
model, and thus negatively regulated synaptogenesis and neurite outgrowth through the
reduction of BDNF, attenuation of BDNF-mediated signalling and impairment of leptin
signalling.
3. Lupeol treatment is able to significantly inhibit PTP1B and reverse PCP-induced
psychopathological alterations to increase BDNF, restore BDNF-mediated signalling
and leptin signalling, as well as enhance the treatment efficacy and prevent side effects
of current antipsychotic such as olanzapine.
4. An innovative microfluidic device is able to separate neurons and glial cells with
efficacy and efficiency. Collected neurons and glial cells are healthy and functional to
perform downstream experiments.
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1.5 Significance
1. One challenge in PTP1B inhibition is that most PTP1B inhibitors target the PTP1B
active site. The PTP1B active site and nearby catalytic domains are highly conservative
in the PTP family. For example, PTP1B is highly similar to TCPTP in amino acid
sequence and 3D structure. To inhibit PTP1B with enhanced selectivity, PTP1B
allosteric site has been discovered as a novel drug target. PTP1B allosteric inhibition is
able to prevent the conformational change of the WPD loop during catalysis, thus
keeping PTP1B in an inactivated state. In the present project, I aim to identify lupane
triterpenes (lupeol, lupenone, betulin and betulinic acid) as novel PTP1B allosteric
inhibitors.
2. Reduction of BDNF and attenuation of BDNF-mediated signalling lead to impaired
neurogenesis which has been recognized in mental disorders including schizophrenia.
PTP1B has been reported to attenuate BDNF-mediated signalling. PTP1B has also been
revealed to inhibit leptin signalling which is a crucial factor stimulating BDNF
expression. Therefore, it is important to investigate the role of PTP1B in the impairment
of BDNF-mediated signalling and whether PTP1B directly regulates BDNF expression
through leptin signalling in schizophrenia-mimicked models.
3. In the present study, lupane triterpene treatment is applied to the PCP treated model
to reverse PCP-induced alterations including BDNF reduction, BDNF-mediated
signalling attenuation and synaptogenesis impairment. Furthermore, lupane triterpene
treatment is applied combined with antipsychotic (olanzapine) treatment to confirm the
improved efficacy of co-treatment due to PTP1B inhibition.
4. Neurons are of particular interest in investigating the psychopathology of mental
illness including schizophrenia. Primary neuron culture is broadly used to collect and
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analyse neurons in mammalian brain tissue. However, it is difficult to isolate purified
neurons from cell mixture in brain tissue culture. In the present study, a microfluidic
device is introduced to separate and collect neurons and glial cells with high purity and
viability. Moreover, such application will be useful in future studies to differentiate the
role of neurons and glia in disease development and will be established as drug
screening platform.
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1.6 Methods and Materials
1.6.1 Homology modelling of PTP1B
In this study, a published PTP1B crystal structure (PDB id: 1T49) was applied. This
PTP1B structure was an open and inactive conformation which contains 282 amino
acids, and the 7 (17 amino acids) was not resolved (labelled as PTP1B282). Helix 7
plays a crucial role in PTP1B allosteric inhibition. However there is no PTP1B crystal
structure with 7 in the inactive state. Here, homology modelling with Modeller 9v8
was performed in order to construct the missing helix 7 based on the active
conformation of PTP1B (PDB id: 1PTY) (labelled as PTP1B299) (Sali and Blundell,
1993). The best PTP1B299 model based on the DOPE energy was chosen from total
100 models generated, and then subjected to equilibrium molecular dynamics
simulations for 40 ns to reach equilibrium and optimize the modelled structure.
1.6.2 Molecular docking
Autodock Vina (version 1.1.2) was used to carry out docking studies (Trott and Olson,
2010). The docking process was established via re-docking previous demonstrated
PTP1B allosteric inhibitor, compound 2 to PTP1B282 as in the co-crystal structure
(Wiesmann et al., 2004). The protonation states of the PTP1B titratable groups were
assigned at pH 7.0 using PROPKA3.1 (Olsson et al., 2011). Docking study was then
performed sequentially in two steps. Firstly, blind docking was performed in which a
cube large enough to cover the whole PTP1B protein (75 Å  60 Å  60 Å) was
established to detect potential binding pockets. Then, focused docking which involved
localized docking with a smaller cube (22.5 Å  22.5 Å  22.5 Å) was set up, targeting
the potential binding site of interest (e.g. active site, allosteric site, or other sites of
interest identified from the previous blind docking procedure). In each focused docking
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study of lupane triterpenes binding to PTP1B282 and PTP1B299, total 20
conformations of the PTP1B-ligand complexes which showed lowest binding affinities
were listed for further analysis. The best binding mode from docking study was selected
as the initial structure for the following molecular dynamics simulations. Multiple
dockings based on different snapshots collected from equilibrium molecular dynamics
simulations (PTP1B282 and PTP1B299), were also performed. Qualitatively, the
identified populated binding poses are similar. In addition, blind docking of lupane
triterpenes targeting TCPTP (1L8K) was performed.
1.6.3 Molecular dynamics simulations
Molecular dynamics simulations were established to characterise the stability and
flexibility of the PTP1B-lupane triterpenes complexes. In this study, total 9 different
systems were set up (PTP1B282, PTP1B282 with Compound2, PTP1B282 with Lupeol,
PTP1B299, PTP1B299 with Compound2, PTP1B299 with Lupeol, PTP1B299 with
Lupenone, PTP1B299 with Betulin, PTP1B299 with Betulinic acid). All of the systems
were solvated in a box full of TIP3P water molecules, which extended about 12 Å from
the surface of the protein. Then counter ions of Na+ were applied to neutralize the
systems. The salt (NaCl) concentration was set to 0.15 mol/L. Molecular dynamics
simulations were carried out using NAMD 2.9 (Phillips et al., 2005). The protein and
the ligands were represented with the GAFF force field (Wang et al., 2004) and the nonpolarizable CHARMM PARAM27 force field (MacKerell et al., 1998), respectively.
Langevin algorithm was applied to set up periodic boundary conditions for all of the
systems, maintaining the temperature at 298.15 K, and the Langevin Piston NoseHoover method was used to keep the pressure constant at 1.0 bar. Particle Mesh Ewald
(PME) method (Darden et al., 1993) was performed to calculate the electrostatic
interactions. The van der Waal forces were treated with a cut-off at 12 Å. All of the
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covalent bonds which involved hydrogen were kept rigid applying the Rattle algorithm
and the time step was set to 1.0 fs. In the equilibrium simulations of PTP1B homology
modelling, a harmonic restraint on the backbone atoms except 7 was established with
a decreasing force constant from 64.0 to 1.0 kcal/mol/Å2 for 10 ns. The simulations
continued for 30 ns without any restraints. For the molecular dynamics simulations of
the docked complexes, a harmonic restraint on the backbone atoms was setup with a
decreasing force constant from 32.0 to 1.0 kcal/mol/Å2 for 3 ns followed by 20 or 100
ns equilibrium simulations.
1.6.4 Binding free energy calculation
Free energy perturbation distributed replica-exchange molecular dynamics (FEP/REMD) (Woods et al., 2003, Jiang et al., 2009) was carried out to calculate binding free
energy of lupeol and betulinic acid binding to PTP1B. The reason to perform
computationally intensive absolute binding free energies is because the binding modes
for lupeol and betulinic acid revealed by docking and subsequently molecular dynamics
simulations are rather different. Therefore it is difficult to apply relative binding free
energy calculations, which assume that the available conformational spaces are strongly
overlapped (Hansen and van Gunsteren, 2014). Based on previous literature, free energy
difference was called between the unbound ligand in the aqueous solution and the
bound ligand in the binding site of the target protein as the absolute binding free
energies. The total free energy was divided into four terms, namely repulsive and
dispersive components of the Lennard-Jones potential based on the Weeks-ChandlerAnderson scheme, the electrostatic contribution, and the restraining potential. Ligand
was decoupled from the environment in four steps through four thermodynamic
coupling parameters (). No corrections have been carried out to the potential
electrostatic finite-size artefacts (Rocklin et al., 2013, Reif and Oostenbrink, 2014). In
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order to accelerate the convergence, each -staging FEP window was treated as a
replica and the -exchange occurred along the entire alchemical reaction path. This
method has been successfully applied to study which investigated the interactions
between glycoside hydrolases and polysaccharides (Payne et al., 2013). For both
PTP1B-lupeol and the PTP1B-betulinic acid complex in this study, FEP/-REMD
simulations started from a 100 ns equilibrated snapshot. Total set of 64 replicas
including 36 repulsive, 12 dispersive, and 16 electrostatic, was carried out in the
simulations with an exchange frequency of one every 1,000 steps (1 ps). In each replica,
1.0 ns simulations were performed in which the last 0.8 ns simulations were averaged to
calculate the ligand binding free energies. The protein-ligand complexes contained a
positional translational restraint with a force constant of 10.0 kcal/mol/Å2. The error
analyses were assigned using four sequential simulations of 0.2 ns each.
1.6.5 Trajectory analysis
Trajectory snapshots were saved every picosecond (i.e. every 1,000 steps). Either the
molecular visualization program VMD 1.9 (Humphrey et al., 1996) or CHARMM
(Brooks et al., 2009) was performed to analyse the trajectory data.
1.6.6 PTP1B and TCPTP inhibition assay of lupane triterpenes by pNPP
phosphatase assay
EnzoLyte Colorimetric pNPP Protein Phosphatase Assay kit (AS-71105, Anaspec) was
applied to determine the inhibitory effects of lupane triterpenes targeting PTP1B and
TCPTP. The recombinant human PTP1B (ab42572, Abcam Inc), recombinant human
TCPTP (ab42575, Abcam Inc), Lupeol (L5632, Sigma-Aldrich), lupenone (1617-70-5,
Faces Biochemical Co.Ltd), betulin (B9757, Sigma-Aldrich), betulinic acid (B8936,
Sigma-Aldrich) and compound 3 (765317-72-4, Merck Millipore) were dissolved in
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Dimethyl sulfoxide (DMSO) or water. Experiment was processed based on
manufacturer instructions. Briefly, 25 ng PTP1B or TCPTP was incubated in different
concentrations of compounds (control drug compound 3, lupeol, lupenone, betulin,
betulinic acid) for 10 min in assay buffer (assay kit supplied) at 25C, and then the
reaction was initiated by adding the 20 mM pNPP reagent and stopped by NaOH (assay
kit supplied) after 30 min at 25C. All readings were detected and recorded using a
spectraMAX 384 microplate spectrophotometer. The absorbance was set up at 405 nm.
Negative control wells without enzymes were calibrated. The PTP1B and TCPTP
inhibition potency of the lupane triterpenes was determined by IC50, calculated using the
GraphPad Prism 5 program (GraphPad Software Inc).
1.6.7 PTP1B inhibition kinetics assay of lupane triterpenes by pNPP phosphatase
assay
The kinetics assay of PTP1B-catalysed hydrolyses in the presence of betulin and
betulinic acid were performed using the pNPP Protein Phosphatase Assay kit described
above. The reaction mixture consisted of six different concentrations of pNPP (1.0, 2.0,
4.0, 8.0, 16.0, and 20.0 mM) as PTP1B substrate and different concentrations of lupeol,
betulin, and betulinic acid. The Lupeol group was set up as a control group. The
absorbance

at

405

nm

was

detected

by

a

spectraMAX

384

microplate

spectrophotometer twice every minute for a total of 15 min. Michaelis-Menten constant
(Km) and maximum velocity (Vmax) of PTP1B were determined via Lineweaver-Burk
plots using the GraphPad Prism 5 program (GraphPad Software Inc).
1.6.8 Immunoprecipitation assay of PTP1B
Based on the instructions of the Pierce Classic IP Kit (26146, Thermo Fisher Scientific
Inc) with minor modifications (Lorenz, 2011), PTP1B was detected using the 25 𝜇g
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PTP1B antibody (sc-1718, Santa-Cruz) for 12 h at 4℃ to form immune complexes.
Immune complexes were then isolated by adding the protein G-agarose, washed three
times in the phosphatase assay buffer from the EnzoLyte Colorimetric pNPP Protein
Phosphatase Assay kit (AS-71105, Anaspec), and resuspended in the same buffer.
Samples were analysed for the phosphatase activity using the same pNPP assay kit
mentioned above.
1.6.9 Ethics statement
This study was approved by the Animal Ethics Committee, University of Wollongong
(Application Approval #: AE15/13 and AE16/01), and complied with the ‘Australian
Code of Practice for the Care and Use of Animals for Scientific Purposes’ (Australian
Government National Health and Medical Research Council, 2004), in accordance with
the International Guiding Principles for Biomedical Research Involving Animals. All
efforts have been performed to minimize animal numbers, animal stress and prevent
suffering.
1.6.10 Primary cell culture of wide type and Nrg1 -/+ mouse hypothalamic neurons
In chapter 3 and chapter 4, primary hypothalamic cell cultures from hypothalamic
tissues of postnatal day 0 (PN0) wild-type (WT) and Neuregulin-1 (NRG1)-knockout
(KO) C57BL/6 mice were prepared based on previous literature (Hilgenberg and Smith,
2007). The culture medium was adapted according to Johns Hopkins online protocol
(Medicine, 2015), which was composed of 480 ml NeuroBasal medium (21103-049,
Gbico) with additive 10 ml B27 (17504-044, Gbico), 5ml glutamine (25030081,
Thermo Fisher Scientific Inc), 5 ml penicillin-streptomycin (15140122, Gbico) and 9 g
glucose (G7021, Sigma-Aldrich). Neurons were plated at either a final density of 1.5 ×
105 cells per cm2 onto Poly-D-Lysine-coated coverslips for immunofluorescence
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imaging (G400-13, ProSciTech) or a final density of 5 × 105 cells per cm2 into Poly-DLysine-coated 12-well cell culture plate for collect protein or RNA, and maintained at
37°C with 5% CO2. At DIV 10, 25 µM PCP (P3209, Sigma-Aldrich) was applied to
neurons for 3h and 48h. To investigate effect of PCP on leptin signalling, 100 nM leptin
(450-31-5000, PeproTech) was applied to neurons after PCP stimulations for 4 hours.
To examine the influence of PTP1B inhibition on neurite synaptogenesis, 50 µM lupeol
(L5632, Sigma-Aldrich) was administrated to primary hypothalamic neurons which
have been treated by 25 µM PCP for 24 hrs, and then co-incubated for another 24 hrs.
The DMSO concentration was controlled below 0.5%. Neurons were then collected for
further experiments including immunofluorescence imaging, qRT-PCR and western blot.
1.6.11 Mouse hypothalamic cell line culture
The mouse hypothalamic A-59 neurons (mHypoA-49 neurons, CELLutions) and mouse
hypothalamic E-46 neurons (mHypoE-46 neurons, CELLutions) were grown in
monolayer in Dulbecco’s modified Eagle medium (DMEM) (D5796, Sigma-Aldrich)
with 10% foetal bovine serum (FBS) (SFBS-F, Bovogen Biologic.Pty.Ltd) and 1%
penicillin/streptomycin. Hypothalamic cells were maintained at 37C with 5% CO2. In
Chapter 2, to detect PTP1B inhibition of lupeol and betulinic acid, Murine TNFα
(T7539, Sigma-Aldrich) was applied to induce PTP1B expression in cell, Lupeol and
betulinic acid were dissolved in Dimethyl sulfoxide (DMSO), then diluted in sterile
water, and mixed with serum free cell culture medium. The DMSO concentration was
controlled below 0.5%. The final concentrations of lupeol and betulinic acid in the cell
culture medium were 28 µM (5 of the IC50 value) and 7.5 µM (5 of the IC50 value),
respectively. In chapter 3, to expose the role of PCP in hypothalamic cell line,
administration of 1 µM PCP (low dosage) or 25 µM PCP (high dosage) (P3209, Sigma-
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Aldrich) were applied to neurons for 3 and 48 hrs. To investigate the NMDA receptor
subunit involved in PTP1B expression, both low dosage (5 µM) and high dosage (50
µM) of NR2A antagonist Peaqx (I2892, Sigma-Aldrich) and NR2B antagonist
ifenprodil (P1999, Sigma-Aldrich) were administrated to cell line for 24 and 48 hrs. To
reveal the signalling pathway involved in PCP induced leptin signalling dysfunction,
100 nM leptin (450-31-5000, PeproTech) was administrated to cells for 4 hrs after PCP
3 and 48 hrs. Prior to leptin treatment, the cell culture medium was replaced with serum
free medium for 4 hrs. To investigate the effect of PTP1B inhibition in hypothalamic
cells, 10 µM and 50 µM PTP1B inhibitor Lupeol and 5 µM atypical antipsychotic
Olanzapine (O1141, Sigma-Aldrich) were dissolved in Dimethyl sulfoxide (DMSO),
then diluted in sterile water, and mixed with serum free cell culture medium. Cells were
exposed to 25 µM PCP for 48 hours and replaced with serum free cell culture medium,
then lupeol treatment, olanzapine treatment and co-treatment were applied to cells for
24 hrs individually. The DMSO concentration was controlled below 0.5%.
1.6.12 Immunofluorescence and image analysis
For immunochemical staining, primary neurons and primary glial cells were washed by
PBS and fixed with 4% paraformaldehyde in Dulbecco's PBS for 30 min at room
temperature. The samples were further incubated with 100% methanol for 10 min in 20°C, and blocked with 5% donkey serum in phosphate buffered saline teween20
(PBST) for 1 hr at 37 °C. Then, anti-PTP1B antibody (SAB1306060, Sigma-Aldrich),
anti-BDNF antibody (SC-20981, Santa-Cruz), anti-SYN antibody (701503, Life
Technnology), anti-microtubule-associated protein 2 (MAP2) antibody (M9942, SigmaAldrich), anti-NeuN antibody (MAB377, Merck Millipore) and anti-Glial Fibrillary
Acidic Protein (GFAP) antibody (G9269, Sigma-Aldrich) were applied overnight at 4°C.
PTP1B, SYN, BDNF and GFAP were visualized with isotype-specific donkey anti-
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rabbit IgG (H+L) secondary antibody conjugated with Alexa Fluor 488. MAP2 and
NeuN were visualized by donkey anti-mouse IgG (H+L) secondary antibody conjugated
to Alexa Fluor 594. The concentrations of antibodies were applied following
manufacturer manuals. A confocal microscope (Leica TCS SP5 Advanced System,
Leica

Microsystem)

was

used

to

obtain

images.

Software

Image

J.

10

(http://rsbweb.nih.gov/ij/download.html) with plugin NeuriteQuant (Dehmelt et al.,
2011) was applied to quantify the immunoreactivity based on from 5 independent
culture wells.
1.6.13 Quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was performed as previously described (Yu et
al., 2013b). Neurons were collected for RNA extraction via AurumTM Total RNA Mini
Kit (7326820, Bio-Rad Laboratories) and reversed to cDNA by using Applied
BiosystemsTM High Capacity cDNA Reverse Transcription Kit (4368814, Life
Technology). Real-time PCR was then performed via SensiFASTTM SYBR No-ROX
Kit (BIO-98005, Bioline).

The mRNA expression levels of PTP1B (Forward:

TGGCCTGACTTTGGAGTCCC; Reverse: CTCCAGTGTGCGTTTGGGTG.), SYN
(Forward:

GAACAAGTACCGAGAGAACAACAA;

GGTCAGTGGCCATCTTCACA.),

Reverse:

BDNF

(Forward:

GGGTCACAGCGGCAGATAAA; Reverse: GCCTTTGGATACCGGGACTT.) and
TCPTP

(Forward:

AGAGTGGCCAAGTTTCCAG;

CACACCATGAGCCAGAAATG.)
GCTAACAGAGAGAAGATGACG;

were

normalized

Reverse:

to

γ-actin

Reverse:
(Forward:

CAGATGCATACAAGGACAGC),

which served as the internal control. Experiments were performed in triplicate.
1.6.14 Western blot analysis
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Detailed protocols were described in our previous study (Yu et al., 2013b), primary
cultured hypothalamic neurons, mHypoA-59 cells and mHypoE-46 cells were washed
with ice-cold phosphate buffered saline (PBS) and lysed in NP-40 lysis buffer
(FNN0021, Invitrogen) containing a protease inhibitor cocktail, beta-glycerophosphate
(Sigma-Aldrich) and phenylmethanesulfonyl fluoride (PMSF) (Sigma-Aldrich). Cell
lysates were centrifuged at 14,000 rpm for 10 min at 4C. The supernatants were
collected and protein concentrations were determined using the DCTM Protein Assay kit
(5000121, Bio-Rad Laboratories) was used according to the manufacturer instructions.
Equal amounts of protein (15 𝜇g) were separated on 4-20% CriterionTM TGX TM Precast
Gels (567-1095, Bio-Rad Laboratories) using SDS-PAGE. Following electrophoresis
(120 V for 1.5 h), the proteins were transferred to polyvinylidene difluoride membranes
(100 V for 1 hr). Membranes were blocked in 5% bovine serum albumin (BSA) or 5%
skim milk depending on the primary antibodies used, followed by incubation with the
primary antibodies anti-PTP1B (SAB1306060, Sigma-Aldrich), anti-BDNF antibody
(SC-20981, Santa-Cruz), pNR2BTyr1472 (4208S, Cell Signaling Technology), NR2B
(4207S, Cell Signaling Technology), anti-pAktSer473 (D9E, Cell Signaling Technology),
anti-Akt (SC8312, Cell Signaling Technology), anti-pGSK3βSer9 (5B3, Cell Signaling
Technology), GSK3β (D75D3, Cell Signaling Technology), pJAK2Tyr1007/1008 (C80C3,
Cell Signaling Technology), JAK2 (D2E12, Cell Signaling Technology), pSTAT3Tyr705
(D3A7, Cell Signaling Technology), STAT3 (79D7, Cell Signaling Technology) and
anti-actin (MAB1501, Merck Millipore) in 1% BSA or 1% skim milk overnight at 4C.
Following washes (3 x 5 min) in Tris Buffered Saline + 0.1% Tween 20, membranes
were incubated with respective secondary antibodies for 1 hr at 25C. Blots were
visualized using AmershamTM ECLTM Detection Reagents (RPN2106, Ge Healthcare)
and exposed in dark room. The bands corresponding to the proteins of interest were
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scanned and analysed using the automatic imaging analysis system Quantity One (BioRad Laboratories). All quantitative analyses were normalized to actin.
1.6.15 Neuron Neuropeptide Y (NPY) detection
The

mouse

hypothalamic

NPY/GFP

neurons

(mHypoA-NPY/GFP

neurons,

CELLutions) were cultured in the 96-well plate in the same incubation condition as
mHypoA-59 neurons. 5µM olanzapine, 50µM lupeol and co-treatment of olanzapine
and lupeol were applied to neurons. After 6h treatment, discard culture medium and
measure neuron NPY-bound GFP immunoactivity using FlexStation 3 (Molecular
Devices). Wavelength of detection is set from 488 nm to 510 nm, cut-off at 495 nm.
1.6.16 Design and fabrication of inertial microfluidic device
The serpentine channel used in our experiments consists of 15 zigzag periods; the
channel has a uniform 42 µm depth, and the length and width of each U-turn are 700
µm. The micro-channel is 200 µm wide. A trifurcating outlet at the end of the channel is
implemented at the end of the serpentine channel. Two-sided symmetrical bifurcations
are combined into a single outlet to simplify the collection of two-sided streams. The
microfluidic device was fabricated by the standard photolithography and soft
lithography techniques (Duffy et al., 1998) (provided by collaborator). Prior to these
cell experiments, the device was rinsed with phosphate buffered saline (PBS) at 100
µl/min for 10 min using a syringe pump (Legato 100, Kd Scientific), after which the
devices were sterilized through exposure to UV light for 30 min.
1.6.17 Inertial microfluidic separation of neurons and glia
Primary neurons and glia were prepared based on 1.6.10, Hypothalamic tissues were
digested and triturated to suspend cells in 7 ml culture medium. 2 ml cell suspension
was assigned as an Inlet group for comparison, while the other 5 ml suspension of
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hypothalamic cell mixture was infused into the inertial microchip to perform separations
under different flow rates (350 µl/min, 550 µl/min, 750 µl/min). Separated cells were
collected from the Outlet Middle and Outlet Aside under three typical flow rates
respectively. Separation efficacy was applied to determine the optimal flow rate. Cells
separated from optimal flow rate were collected for further culture and tests. Purity of
separation and enrichment ratio were measured to evaluate separation performance.
Separation purity is defined as the ratio of target cells number to the total cells number,
while enrichment is determined as the ratio of target cells concentration from the outlet
to the target cells concentration from the inlet.
1.6.18 Statistical analysis
Data in the present study were analysed using the SPSS 19 statistical package (SPSS,
Chicago, IL). T-test and One-way analysis of variance (ANOVA) followed by the posthoc Tukey-Kramer honestly significant difference (HSD) test were carried out based on
individual experiments. Data were expressed as mean ± SEM, and P < 0.05 was
considered statistically significant.
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1.7 Summary
Current challenge in PTP1B drug discovery was mentioned that PTP1B traditional
inhibitors hardly inhibit PTP1B with potency, selectivity and lack of bioavailability.
PTP1B traditional inhibitors target PTP1B active site, which is highly similar to other
members of PTPs in both amino acid sequence and 3D structure. Therefore PTP1B
allosteric inhibition was introduced which targets PTP1B unique allosteric site, making
PTP1B allosteric inhibition as a promising strategy for drug discovery. Here I proposed
lupane triterpenes as PTP1B allosteric inhibitors candidates based on the properties
shown in previous literatures. Computational modelling combined with biological
assays and cell culture will be applied to confirm lupane triterpenes as PTP1B allosteric
inhibitors.
Furthermore, I reviewed the rising evidences which reported that PTP1B impaired
neurite outgrowth and synaptogenesis via attenuating BDNF-mediated signalling. All
these evidences indicated that PTP1B may have a crucial role modulating impaired
neurogenesis in neurological disorders such as schizophrenia and PTP1B inhibition
could be an alternative medication treatment. Phencyclidine (PCP)-treated model and
neuregulin-1 knock-out model were introduced which have been broadly applied to
mimic psychopathology of schizophrenia and testify treatment effects. Both models will
be applied to investigate the role of PTP1B contributing to BDNF reduction and
attenuation of BDNF-mediated signalling. Moreover, lupane triterpene will be applied
to determine that PTP1B inhibition is a potential therapeutic strategy.
At last, the current issue in primary cell culture was discussed which is the difficulty to
collect purified and enriched neurons and glia without chemical reagent and antibody
disturbance. In the present study, inertial microfluidic microchip will be introduced to
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spontaneously separate and collect both neurons and glia. Importantly, interest in glial
cell is rising due to increasing evidences revealed the glia dysfunction in several brain
disorders

including

schizophrenia

with

significant

cognitive

impairments.

Consequently, an effective and efficient platform is required to separate and collect
neurons and glia from the same brain section of interest at the same time to establish coculture system in the future study, Microfluidic-based technology will meet this
requirement and broadly applied in the future study.
In conclusion, the present study will firstly apply computational modelling and
biological assays to determine lupane triterpenes as novel PTP1B allosteric inhibitors in
chapter 2. Then schizophrenia-mimicked models will be used to investigate the role of
PTP1B in BDNF reduction and neurogenesis impairment, and determine PTP1B
allosteric inhibition by lupane triterpenes is a potential therapeutic strategy in chapter 3.
Inertial microfluidic separation to collect purified and functional neurons and glia will
be performed and discussed in chapter 4.
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Chapter Two
Selective binding modes and allosteric inhibitory effects of lupane triterpenes on protein
tyrosine phosphatase 1B
Reprinted from Scientific Report, Open-access
Available at: http://www.nature.com/articles/srep20766
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Chapter Three
Protein Tyrosine Phosphatase 1B mediates phencyclidine-induced BDNF reduction and
neurogenesis impairment in hypothalamic neurons
Submitted to Scientific Report on 2016.7
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Abstract:
Protein Tyrosine Phosphatase 1B (PTP1B) inhibits BDNF-mediated signalling and
attenuates leptin signalling, which can impair neurite outgrowth and synaptogenesis. On
antagonizing the N-methyl-D-aspartate receptor (NMDAR), we found that the
psychotomimetic

drug

phencyclidine

(PCP)

reduces

neurite

outgrowth

and

synaptogenesis with a significantly increased PTP1B in the hypothalamic neurons. We
further characterised that it is NR2B, but not NR2A antagonist responsible for the
increased PTP1B. Moreover, PTP1B was increased in the hypothalamic neurons of
neuregulin-1 knock out mice in which the decreased hypothalamic NR2B
phosphorylation was confirmed. PCP decreased neurite outgrowth and synaptogenesis
via an increased PTP1B and decreased BDNF level, BDNF-mediated-Akt/GSK3β, and
synaptophysin. Furthermore, leptin increases BDNF expression and promotes
synaptogenesis which is also impaired by PCP-induced PTP1B. PTP1B directly
inhibited JAK phosphorylation and thus attenuated leptin signalling and pSTAT3,
leading to reduced BDNF. Therefore, we proposed that PTP1B-JAK2-STAT3 pathway
contributed to PCP-induced BDNF reduction. Importantly, we showed that lupeol, a
specific PTP1B allosteric inhibitor, significantly reduced PTP1B expression and
improved antipsychotic drug’s effect on BDNF, leptin signalling, neurite outgrowth and
synaptogenesis,

as

well

as

prevent

antipsychotic

drug

induced

orexigenic

neurotransmitter, neuropeptide Y (NPY) production.

Key words: PTP1B; phencyclidine; BDNF; leptin; PTP1B allosteric inhibitor
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Significance Statement: This study determined hypothalamic PTP1B as a new
contributor to BDNF reduction and neurogenesis impairment in phencyclidine (PCP)mimicked schizophrenia model. BDNF reduction was broadly observed in
schizophrenia patients and PCP models however the mechanism remains unclear. Here
we characterised that PCP-induced PTP1B directly inhibited pJAK2 which blocked
leptin signalling and downstream pSTAT3, resulting in reduction of BDNF protein and
mRNA level, further attenuated BDNF-mediated Akt/GSK3β and synaptogenesis in
PCP-treated model. Therefore we proposed PTP1B as a new drug target to reverse PCPinduced alterations. PTP1B allosteric inhibitor was applied which significantly restored
BDNF and improved antipsychotic drug, olanzapine’s treatment effect. PTP1B is an
obesity related protein. Here PTP1B inhibition prevented olanzapine-induced
neuropeptide Y production which caused obesity as side effects in clinical.
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Introduction:
Protein Tyrosine Phosphatase 1B (PTP1B) is highly expressed in the brain tissue.
Studies have shown that PTP1B influences neurite outgrowth, synaptogenesis and
cognition. For example, the reduction of hippocampal PTP1B expression improves
dendritic filopodia, learning and memory (Fuentes et al., 2012). An overexpression of
PTP1B decreases brain derived neurotrophic factor (BDNF) and its receptor TrkB
signalling; however, inhibition of PTP1B restores BDNF-mediated neurite outgrowth
and synaptogenesis (Ozek et al., 2014). Krishnan etc. further demonstrated PTP1B as a
negative regulator of tyrosine phosphorylation of TrkB to inhibit BDNF signalling in
neurological disorder in Rett syndrome model (Krishnan et al., 2015). PTP1B is
expressed in the hypothalamus, in which a neuropathology of schizophrenia has been
indicated (Fannon et al., 2000, Zabolotny et al., 2002, Walker et al., 2008, Bernstein et
al., 2010). Decreased BDNF expression is found in a number of mental disorders
including schizophrenia (Angelucci et al., 2005, Favalli et al., 2012). Therefore it is of
great interest to investigate the role of hypothalamic PTP1B in modulating BDNFmediated neurite outgrowth and synaptogenesis in schizophrenia relevant cell models.
Previous study shows that PTP1B attenuates leptin signalling (Zabolotny et al., 2002).
The adipocyte-secreted hormone leptin promotes synaptogenesis and maintains neural
dendritic morphology as well as regulates energy homeostasis and facilitates learning
and memory (Bariohay et al., 2005, Komori et al., 2006, Yamada et al., 2011). Leptin
increases neurite outgrowth and synaptogenesis in mouse H19-7 HN neural cell lines, as
well as stimulates hippocampal neurogenesis by increasing cell proliferation and
differentiation (Moon et al., 2013), while memory deficits or decreased synapse density
has been reported in leptin or leptin receptor deficient rodents such as ob/ob mice, db/db

77

`

mice and fa/fa rats (Li et al., 2002, Bouret et al., 2004, Pinto et al., 2004, Farr et al.,
2006). Leptin stimulates BDNF expression in the dendrites of hypothalamic neurons
(Liao et al., 2012). Leptin signalling is activated by Janus Kinase 2 (JAK2)
phosphorylation and leads to downstream signal transducer and activator of
transcription 3 (STAT3) expression (Bjorbaek and Kahn, 2004), which has been
confirmed to benefit neurite outgrowth (Miao et al., 2006, Ng et al., 2006).
Phencyclidine (PCP), a non-competitive N-methyl-D-aspartate (NMDA) receptor
antagonist, can induce schizophrenia-like behaviors in humans and rodents (Morris et
al., 2005). It is known that PCP decreases neurite outgrowth and dendritic spine density
both in vitro and in vivo (Hajszan et al., 2006, Adachi et al., 2013). However, the exact
mechanism is still unclear. It is known that PCP decreases BDNF expression and its
downstream Akt and GSK3β expression (Adachi et al., 2013). Recently, PTP1B has
been revealed to inhibit BDNF signalling (Ozek et al., 2014, Krishnan et al., 2015). We
hypothesize that PTP1B may be involved in PCP induced reduction of BDNF and
impaired Akt and GSK3β signalling pathway. Furthermore, leptin has been revealed to
stimulate NMDA-induced intracellular Ca2+ levels and facilitates NMDA in modulating
synaptic plasticity (Shanley et al., 2001). Therefore it will be interesting to investigate
whether PTP1B is involved in linking NMDA hypofunction and leptin signalling in
PCP-mimicked schizophrenia modelling.
In this study, PCP was administrated to primary hypothalamic neurons and
hypothalamic cell line to examine if hypofunction of NMDA receptor enhance PTP1B
expression, followed by investigation of NMDA receptor subunit 2A (NR2A) or
NMDA receptor subunit 2B (NR2B) specific effect using their antagonists.
Furthermore, PCP’s effects on BNDF and its downstream signalling, synaptogenesis
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and leptin signalling were examined. To investigate if these specific effects induced by
PCP were via PTP1B, Lupeol, PTP1B allosteric inhibitor, was pretreated to prevent
PCP’s effects. Furthermore, co-treatment of lupeol and antipsychotics, olanzapine were
applied to investigate if hypothalamic PTP1B as a potential target to improve mental
disease treatment such as schizophrenia.
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Results:
PTP1B expression responds to PCP stimulation
In a hypothalamic cell line, we observed the dose and time response effects of PTP1B
expression following PCP administration. After 3 hours treatment, PCP significantly
increased PTP1B (+50%) expression at dose 25µM but not 1µM (Fig.1a). After 48
hours treatment, PCP increased PTP1B in both 25µM (+60%) and 1µM (+30%) doses
(Fig.1b). PCP increases PTP1B in dose and time dependent manner. In primary culture
(DIV 10) of hypothalamic neurons, we treated the neurons with 25µM PCP for 3 and 48
hours. PTP1B immunoreactivity level was observed with 1.5-fold increase compared to
control after 48-h treatment by quantification of MAP2-positive living cells (Fig.1c and
1d). To confirm our findings, we used RT-PCR to examine the PTP1B mRNA level.
We observed similar results as there was a 2.2-fold increase in PTP1B mRNA level
after 48 hours of 25µM PCP treatment (Fig.1e).
NR2B antagonist, but not NR2A antagonist, increases PTP1B expression in the
hypothalamic neurons
PCP is a non-competitive NMDA receptor antagonist (Paoletti and Neyton, 2007).
NMDA receptor consists of NR1 and NR2 subunits. NR2A and NR2B are primarily
responsible for PCP induced behaviour changes in experimental animals (Anastasio et
al., 2009, du Bois et al., 2012). To investigate the role of NR2A and NR2B on PTP1B
regulation, specific NR2A antagonist Peaqx and NR2B antagonist ifenprodil were used
to examine the changes of PTP1B expression in the hypothalamic cells. Both low
dosage (5µM) and high dosage (50µM) of each two antagonists were tested for 24 and
48 hours. After 24 hours exposure, high dose of ifenprodil enhanced PTP1B protein
level (1.5-fold compared to control), while low dose did not significantly increased
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PTP1B (Fig.2a). When the incubation of ifenprodil was extended to 48 hours, low
dosage group showed 1.5-fold increased PTP1B expression compared to control
(Fig.2b). Similar to PCP, NR2B antagonism increases PTP1B expression in both dose
and time dependent manner. However, NR2A antagonist Peaqx showed no change on
PTP1B expression at neither low nor high doses or on 24 and 48 hour stimulation
(Fig.2c and 2d). We suggest that NR2B antagonism is responsible for increased PTP1B
expression in hypothalamic cells. We further confirmed that PCP and ifenprodil
treatments reduced NR2B phosphorylation (Fig.S3).
Neuregulin-1 (Nrg1) gene knockout leads to a decreased pNR2B, but an increased
PTP1B
Previous study showed that NR2B phosphorylation requires normal Nrg1 signalling in
the prefrontal cortical neurons (Zhang et al., 2016). We found that Nrg1 knockout mice
had a significantly decreased NR2B phosphorylation in the primary hypothalamic
neurons (Fig.2e), which is similar to a decreased NR2B phosphorylation and NMDA
receptor hypofunction reported in hippocampal neurons (Bjarnadottir et al., 2007). This
suggests that Nrg1 gene mutation could lead to NR2B hypofunction. Furthermore, we
found a significantly increased PTP1B immunoreactivity level by 1.7-fold in the
hypothalamic neurons of Nrg1 knockout mice compared to wild type mice (Fig.2f and
2g). Furthermore, we showed that 25µM PCP did neither increase PTP1B
immunoreactivity level nor decrease NR2B phosphorylation in Nrg1 knockout mice
(Fig.2f and 2g).
PCP attenuates leptin JAK2/STAT3 pathway and leptin-mediated BDNF level
PTP1B has been reported to dephosphorylate JAK2, a kinase to activate leptin
signalling STAT3 (Ahima and Flier, 2000, Zabolotny et al., 2002). We have shown in
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above that PCP increased PTP1B. In this part of study, we examined leptin signalling
pathway molecules. We used 25µM PCP to treat the hypothalamic cells for 3 hours and
48 hours, followed by100nM leptin treatment for 4 hours. Leptin alone significantly
increased 1.4-fold JAK2 phosphorylation and 1.5-fold STAT3 phosphorylation (Fig.3a)
which was not case in PCP co-treatment groups in neither 3 hours nor 48 hours (Fig.3a),
suggesting that PCP impairs leptin signalling. We further showed that leptin increased
BDNF immunoreactivity level by 45% compared to vehicle group similar to what has
been reported previously (Komori et al., 2006); however, PCP co-treatment group
showed that leptin was no longer able to increase BDNF (Fig.3b and 3c). To confirm
these data, we also measured BDNF mRNA level after leptin treatment or leptin and
PCP co-treatment for 3 and 48 hours, which showed similar findings (Fig.3d).
Therefore, we showed that PCP increased PTP1B and blunted leptin-induced increases
of JAK2, STAT3 and BDNF expression, which could contribute to the reduction of
neurite outgrowth and synaptogenesis induced by PCP.
PCP reduces hypothalamic neuronal BDNF expression
After 3-h treatment, PCP (25µM) significantly (-40%) decreased BDNF expression in
hypothalamic cells, but not at low dose (1µM) (Fig.4a). On the other hand, both low and
high PCP doses reduced BDNF expression after 48 hour treatment (Fig.4b), indicating
that PCP suppressed BDNF protein level in a dose- and time-dependent manner in the
hypothalamic cells. Furthermore, primary culture of hypothalamic neurons (at DIV 10)
were exposed to 25µM PCP for 48 hours showing 70% reduction of BDNF
immunoreactivity level compared to control group (Fig.4c and 4d) and 50% inhibition
of BDNF mRNA level (Fig.4e). Therefore, we have shown that 25µM PCP treatment
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for 48 hours had strongest effect in BDNF expression in both hypothalamic cell line and
primary cultured neurons.
PCP reduces hypothalamic neuronal Akt/GSK3β signalling and synaptic protein
It is known that BDNF increases the levels of the synaptic vesicle proteins
synaptophysin (Tartaglia et al., 2001), in which Akt/GSK3β signalling pathway has
been largely involved (Smillie et al., 2013). Since we have found that PCP increased
PTP1B and reduced BDNF, we then examined if PCP may alter Akt/GSK3β signalling
in the hypothalamic cells. After 3 hours of PCP treatment, both low dose and high dose
of PCP reduced the AktSer473 phosphorylation, while only high dose of PCP significantly
reduced GSK3βSer9 phosphorylation (Fig.4f). After 48-h PCP treatment, both low and
high dose of PCP reduced Akt phosphorylation (1 µM: 45%; 25 µM: 50%) and
inhibited GSK3β phosphorylation (1 µM: 35%; 25 µM: 45%) (Fig.4g). Following the
upregulation of PTP1B and reduction of BDNF-Akt/GSK signalling, the effect of PCP
on the synaptic protein synaptophysin (SYN) as synaptogenesis marker was further
examined in the primary hypothalamic neurons. Both SYN immunoreactivity and
mRNA levels were significantly reduced by 50% and 50% after 25 µM PCP treatment
for 48 hours (Fig.4h, 4i, and 4j). The SYN mRNA level was reduced by 40% after 3
hours of PCP treatment (Fig.4j).
Lupeol, PTP1B allosteric inhibitor, prevents PCP-induced reduction of BDNFAkt/GSK3β signalling and SYN expression
Recently, PTP1B has been is revealed as a novel regulator of central BDNF signalling
(Ozek et al., 2014). PTP1B inhibits BDNF–mediated signalling which is a major
regulator of Akt/GSK3β signalling pathway (Kitagishi et al., 2012). To investigate
whether inhibition of PTP1B could improve BDNF downstream signalling related to
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synaptogenesis, PTP1B allosteric inhibitor Lupeol was used to examine its effects in
prevention of PCP attenuated BDNF signalling in regulation of SYN. We and other
group have confirmed that lupeol is PTP1B specific allosteric inhibitor (Na et al., 2009,
Jin et al., 2016). Based on our previous study (Jin et al., 2016), we applied 50µM lupeol
to hypothalamic cells for 24 hours following 25µM PCP administration for 48 hours.
Lupeol significantly prevented PCP-induced PTP1B (Fig.5a). Simultaneously, Lupeol
reversed PCP-induced decrease of JAK2 phosphorylation by 3 fold (Fig.5a). Also,
Lupeol prevented PCP-reduced BDNF and Akt and GSK3β phosphorylations (Fig.5a
and 5b). In addition, to investigate the effect of PTP1B inhibition on the synaptogenesis,
the SYN immunoreactivity was examined in MAP2-positive primary cultured
hypothalamic neurons treated with 50µM lupeol for 24 hours following 25µM PCP
exposure for 24 hours. Lupeol treatment performed a 1.8-fold increase of SYN
immunoreactivity compared to the control group treated with PCP only (Fig.5c and
Fig.5d). We showed that Lupeol’s inhibition on PTP1B improved synaptogenesis.
Lupeol facilitates olanzapine to reverse PCP-induced alterations and prevent
olanzapine-induced NPY level.
Olanzapine is known to prevent some PCP-induced behaviour changes while the
mechanism is still largely unknown (Patil et al., 2007). In the present study, we
investigated if olanzapine or combination of lupeol and olanzapine could prevent PCP
induced over-expression of PTP1B and its related downregulation of BDNF and
impairment of Akt/GSK3β pathway. 5µM olanzapine with or without 10µM and 50µM
lupeol were administrated to hypothalamic cell line which had been exposed to 25µM
PCP for 48 hours. PTP1B protein level was not significantly decreased by olanzapine
treatment and olanzapine with low dosage of lupeol (10µM). However the co-treatment
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of olanzapine and high dosage of lupeol (50µM) significantly inhibited PTP1B
expression (Fig.6a). Olanzapine significantly increased pAkt and pGSK3β with minor
improvement on pJAK2 and BDNF protein level (Fig.6b and 6c). Co-treatment of high
dosage of lupeol and olanzapine further increased pJAK2, BDNF, pAkt and pGSK3β
compared with olanzapine treatment (Fig.6b and 6c), suggesting lupeol improves
olanzapine’s effect on the enhancement of leptin signalling pJAK2, the increase of
BDNF and Akt/GSK3β pathway activation. Moreover, Olanzapine has been found to
induce weight gain and elevate orexigenic neurotransmitter, neuropeptide Y (NPY)
mRNA level (Weston-Green et al., 2012). Here we measured effects of olanzapine and
lupeol on regulating NPY level using NPY/GFP neurons. There is a 1.4-fold increase of
NPY level in olanzapine treatment however the co-treatment of lupeol and olanzapine
prevented olanzapine-induced NPY level (Fig.6d). Therefore, a combination therapy of
olanzapine with lupeol, a PTP1B allosteric inhibitor, may offer a new strategy for the
prevention and treatment of schizophrenia pathology with reduced side effects such as
weight gain.
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Discussions
This study showed that NMDA and NR2B receptor antagonists (PCP and ifenprodil)
significantly increased PTP1B expression in the hypothalamic neurons in a dose- and
time-manner. Previous study reported that PTP1B expression was decreased in an
oxovanadium complex of glutamic acid suggesting possible glutamate NMDAR
involvement (Lu et al., 2010). One previous study found that NMDA receptor didn’t
form complex with PTP1B based on a proteomic screening of NMDA receptoradhesion protein, suggesting that NMDA receptor in suppression of PTP1B may not via
direct interaction. On the other hand, the authors suggested that the undetected NMDAPTP1B complex might be due to comigration heavy chain during immunoblotting
experiments (Husi et al., 2000). Therefore the relation between NMDA receptor and
PTP1B remains unclear. Further research is required to address if there is possible direct
relationship between NMDAR and PTP1B. PCP is a non-competitive NMDA
antagonist, which inhibits both NR2A and NR2B subunit with poor selectivity (Paoletti
and Neyton, 2007). It was interesting that in the present study, we found that only
application of ifenprodil, but not PEAQX, increased PTP1B expression in the
hypothalamic neurons, suggesting that NR2B antagonism increased PTP1B.
Furthermore, there was a negative relationship between the NR2B phosphorylation and
PTP1B expression in Nrg1 KO mice which supported our finding that NR2B
downregulated PTP1B. Both NR2B deficient and NRG1 gene mutation contribute to the
risk of developing schizophrenia (Stefansson et al., 2002, Bjarnadottir et al., 2007).
Furthermore, recent studies have showed that Nrg1-ErbB4 signalling is required for
NR2B phosphorylation and TrkB interacts with ErbB4 to modulate Nrg1-induced
NR2B phosphorylation (Pandya and Pillai, 2014, Zhang et al., 2016). Interestingly,
PTP1B inhibits TrkB and therefore disturbs Nrg1-induced NR2B phosphorylation
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(Pandya

and

Pillai,

2014),

implicating

a

feedback

loop

between

NR2B

dephosphorylation and PTP1B increase. Here, we showed that PCP was not capable to
increase PTP1B in Nrg1 KO mice. It could be because NR2B phosphorylation has been
inhibited by an increased PTP1B in Nrg1 KO mice. On the other hand, Fyn appears to
play an important role in facilitating NR2B phosphorylation (Bjarnadottir et al., 2007,
Zhang et al., 2016). Fyn belongs to Src family which has a close link to NMDAR
function and scizhophrenia (Pitcher et al., 2011). PTP1B has been revealed to physically
interact Src in intact cells and modulate Src activation (Monteleone et al., 2012). It will
be interesting to investigate the relation of PTP1B and Src contributing to schizophrenia
and relative treatment in the future study. Overall, the findings from the present study
showed that PTP1B was elevated by NMDA receptor blockade and NR2B antagonist
and in Nrg1 KO mice, from which all had NR2B downregulation. Therefore, our
findings indicated that PTP1B is an important mediator contributing to NMDA receptor
hypofunction induced by schizophrenia mimetic drug PCP.
Leptin is known to stimulate neurite outgrowth, synaptogenesis and synaptic plasticity
as well as to improve learning and memory (Li et al., 2002, Bouret et al., 2004, Pinto et
al., 2004, Farr et al., 2006). Moreover, previous studies have reported that leptin
exclusively improves NMDA receptor-regulated synaptic transmission including
induction of long-term potentiation (Shanley et al., 2001, Harvey et al., 2005, Harvey,
2007), indicating that leptin signalling is capable of improving NMDA-mediated
signalling pathway. The present study showed that NMDA receptor antagonism
increased PTP1B which affected hypothalamic leptin signalling, indicating the
interactions between NMDA receptor and leptin signalling pathways. Leptin signalling
is featured by activated JAK2/STAT3 pathway. JAK2/STAT3 plays a key role in
central nerve system involved in the regulation of synaptic plasticity (Nicolas et al.,
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2013) (Nicolas et al., 2012), promoting nerve cell proliferation (Mangoura et al., 2000)
and regulation of energy homeostasis (Villanueva and Myers, 2008). Previous study has
shown that PTP1B inhibits leptin signalling through attenuating JAK2/STAT3 pathway
(Zabolotny et al., 2002). We showed that NMDA receptor/NR2B antagonism increased
PTP1B that could lead to a decreased hypothalamic leptin signalling including pJAK2
and pSTAT3.
A number of studies have reported that PCP decreases BDNF protein and mRNA level
(Snigdha et al., 2011, Adachi et al., 2013, Katanuma et al., 2014, Zhang et al., 2016).
BDNF is an important regulator of synaptic transmission and neural plasticity (Huang
and Reichardt, 2001). Reduction of BDNF protein and BDNF mRNA level has been
reported in the brain of schizophrenia and other mental illness (Weickert et al., 2003,
Weickert et al., 2005, Favalli et al., 2012). Previous study showed that PTP1B
suppresses hypothalamic BDNF and TrkB signalling (Ozek et al., 2014, Krishnan et al.,
2015). In agreement with their study, the present study showed that PCP decreased
BDNF-pAkt-pGSK3β signalling accompanied by an increased PTP1B. It is known that
pAkt/pGSK3β improves synaptogenesis and neurite outgrowth (Kitagishi et al., 2012,
Smillie et al., 2013). For example, pAkt facilitates dendritic spine protein involved in
working memory formation (Emamian et al., 2004). GSK3β has abundant expression in
neurons during brain development and is related to neurite outgrowth and synapse
formation (Leroy and Brion, 1999). Indeed, the present study showed that blockade of
NMDA receptor decreased SYN which was prevented by Lupeol. In the present study,
we found that BDNF was decreased when PTP1B was increased by NMDAR blockade.
In contrast, when PTP1B was inhibited by lupeol, the downregulation of BDNF
expression was prevented, indicating a negative regulatory mechanism between PTP1B
and BDNF. Clearly, PTP1B inhibitor lupeol was capable of preventing a
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downregulation of BDNF via inhibiting PTP1B. These findings suggest that
overexpression of PTP1B may contribute to NMDA hypofunction in reduction of
synaptogenesis via lowering BDNF. While the mechanism of NMDA receptor blockade
decreases BDNF is not known. One possibility is directly related to NMDAR-PSD95Nrg1 signalling to influence BDNF or via a disinhibition effect of PTP1B on
JAK2/STAT3 (Fig.7).
In this study, olanzapine alone did not prevent PCP-induced overexpression of PTP1B
and reduction of leptin downstream JAK2 and BDNF. Lupeol is a PTP1B allosteric
inhibitor (Na et al., 2009, Jin et al., 2016). Lupeol was able to specifically target PTP1B
allosteric site to selectively inhibit PTP1B over other phosphatases including T-cell
protein tyrosine phosphatase (TCPTP). TCPTP shares a 74% identical sequence in its
catalytic domain with PTP1B (Iversen et al., 2002) and they have almost
superimposable active sites. However TCPTP has different biological functions and
signalling pathways from PTP1B as demonstrated in mouse models (You-Ten et al.,
1997, Simoncic et al., 2002). In this study we found that PCP stimulated PTP1B mRNA
level without affecting TCPTP mRNA level (Fig.S1), indicating the requirement to
apply PTP1B inhibitor with selectivity. We showed that a combined treatment of
olanzapine and lupeol, completely blocked PCP-induced PTP1B overexpression and
reductions of pJAK2 and BDNF and reduced pAkt/pGSK3β signalling. Therefore, we
showed that lupeol improved antipsychotic drug olanzapine’s effect in the prevention of
the PCP induced neuronal changes. This study suggests that PTP1B may play a
significant role in psychotomimetic drug induced neuropathology and possible
psychosis. PTP1B inhibition may be a new strategy to improve olanzapine’s therapeutic
efficacy. Furthermore, clinical studies have indicated that obesity is highly prevalent
among patients with schizophrenia (Elman et al., 2006). Olanzapine and other second
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generation of antipsychotics have been reported to increase prevalence of weight gain
side-effects (Cohn et al., 2004, McEvoy et al., 2005, Haupt, 2006, Meltzer et al., 2008).
Recent study has revealed the interactions between olanzapine-induced weight gain and
an elevated orexigenic neurotransmitter, neuropeptide Y (NPY) mRNA level (WestonGreen et al., 2012). Hypothalamic PTP1B inhibition prevents weight gain and decrease
adiposity. We further measured effects of olanzapine and lupeol on regulating NPY
level using NPY/GFP neurons. We demonstrated 1.4-fold increase of NPY level in
olanzapine treatment. Importantly, lupeol treatment prevented olanzapine-induced NPY
level (Fig.6d). Therefore, co-treatment of PTP1B inhibitor, lupeol with olanzapine may
prevent antipsychotic induced weight gain. Considering PTP1B contributes to obesity
development, co-treatment of antipsychotic with PTP1B inhibitors may be a potential
treatment plan.
In conclusion, this study has demonstrated that NMDA receptor blockade significantly
increased PTP1B expression, which is associated with downregulation of NR2B
phosphorylation. Increased PTP1B attenuated leptin signalling and leptin-mediated
BDNF expression through a downregulation pJAK2/pSTAT3 signalling. Furthermore,
an increased PTP1B decreased BDNF expression, and impaired BDNF-mediated
pAkt/pGSK3β pathway and finally suppression of synaptophysin. When we applied a
PTP1B allosteric inhibitor, lupeol significantly reduced PTP1B expression and
prevented the PCP-induced alterations. Lupeol enhanced antipsychotic drug
olanzapine’s effect to prevent increased PTP1B and decreased BDNF expression.
Therefore, PTP1B inhibition may be used as a new treatment to improve therapeutic
efficacy and prevent the obesity induced by antipsychotics.

90

`

Methods and Materials:
Primary culture of wide type and Nrg1 -/+ mouse hypothalamic neurons. Primary
hypothalamic cell cultures from hypothalamic tissues of postnatal day 0 (PN0) wildtype (WT) and Neuregulin-1 (NRG1)-knockout (KO) C57BL/6 mice were prepared
based on previous literature (Hilgenberg and Smith, 2007). The procedures on animals
were approved by the Animal Ethics Committee, University of Wollongong, NSW,
Australia, and carried out in accordance with the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes. The culture condition was adapted
according to Johns Hopkins online protocol (Medicine, 2015). The culture medium was
composed of NeuroBasal medium with additive B27 and extra glucose and glutamine.
Neurons were plated at either a final density of 1.5×105 cells per cm2 onto Poly-DLysine-coated coverslips for immunofluorescence imaging (G400-13, ProSciTech) or a
final density of 5×105 cells per cm2 into Poly-D-Lysine-coated 12-well cell culture plate
for collecting protein or RNA, and maintained at 37°C with 5% CO2. At DIV 10, 25µM
PCP (P3209, Sigma-Aldrich) was applied to neurons for 3h and 48h. To investigate the
effect of PCP on leptin signalling, 100 nM leptin (#450-31-5000, PeproTech) was
applied to neurons after PCP stimulations.
Immunofluorescence and image analysis. For immunochemical staining, neurons
were fixed with 4% paraformaldehyde in Dulbecco's PBS for 30 min at room
temperature. The samples were further incubated with 100% methanol for 10 min in 20°C, and blocked with 5% donkey serum in PBST for 1 hr at 37 °C. Then, anti-PTP1B
antibody (SAB1306060, Sigma-Aldrich), anti-BDNF antibody (SC-20981, Santa-Cruz),
anti-SYN antibody (701503, Life Technnology) and anti-MAP2 antibody (M9942,
Sigma-Aldrich) were applied overnight at 4°C. PTP1B, SYN and BDNF were
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visualised with isotype-specific donkey anti-rabbit IgG (H+L) secondary antibody
conjugated with Alexa Fluor 488. MAP2 was visualised by donkey anti-mouse IgG
(H+L) secondary antibody conjugated to Alexa Fluor 594. The concentrations of
antibodies were applied following manufacturer’s manuals. A confocal microscope
(Leica-TCS-SP5 Advanced System, Leica Microsystem) was used to obtain images.
Software Image J. 10 (http://rsbweb.nih.gov/ij/download.html) was applied to quantify
the immunoreactivity based on from 5 independent culture wells.
Quantitative PCR. Quantitative real-time PCR (qRT-PCR) was performed as
previously described (Yu et al., 2013b). At DIV 10, administration of 25µM PCP
(P3209, Sigma-Aldrich) was applied to neurons for 3 and 48 hours. Neurons were
collected for RNA extraction via AurumTM Total RNA Mini Kit (7326820, Bio-Rad
Laboratories) and reversed to cDNA by using Applied Biosystems TM High Capacity
cDNA Reverse Transcription Kit (4368814, Life Technology). Real-time PCR was then
performed via SensiFASTTM SYBR No-ROX Kit (BIO-98005, Bioline). The mRNA
expression levels of PTP1B (Forward: TGGCCTGACTTTGGAGTCCC; Reverse:
CTCCAGTGTGCGTTTGGGTG.),

SYN

GAACAAGTACCGAGAGAACAACAA;
TCACA.),

BDNF

GCCTTTGGATA

(Forward:

Reverse:

(Forward:
GGTCAGTGGCCATCT

GGGTCACAGCGGCAGATAAA;

CCGGGACTT.)

and

TCPTP

Reverse:
(Forward:

AGAGTGGCCAAGTTTCCAG; Reverse: CACA CCATGAGCCAGAAATG.) were
normalised to γ-actin (Forward: GCTAACAGAGAGAA GATGACG; Reverse:
CAGATGCATACAAGGACAGC), which served as the internal control. Experiments
were performed in triplicate.
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Mouse hypothalamic cell culture. The mouse hypothalamic A-59 neurons (mHypoA59 neurons, CELLutions) were grown in monolayer in Dulbecco’s modified Eagle
medium (DMEM) (D5796, Sigma-Aldrich) with 10% foetal bovine serum (FBS)
(SFBS-F, Bovogen Biologic.Pty.Ltd) and 1% penicillin/streptomycin. Hypothalamic
cells were maintained at 37C with 5% CO2. To expose the role of PCP in hypothalamic
cell line, administration of 1µM PCP or 25µM PCP (P3209, Sigma-Aldrich) were
applied to neurons for 3 and 48 hours. To investigate the NMDA receptor subunit
involved in PTP1B expression, both 5µM and 50µM NR2A antagonist Peaqx (I2892,
Sigma-Aldrich) and NR2B antagonist ifenprodil (P1999, Sigma-Aldrich) were
administrated to cell line for 24 and 48 hours. To reveal the signalling pathway involved
in PCP induced leptin signalling dysfunction, 100nM leptin (450-31-5000, PeproTech)
was administrated to cells for 4 hours after PCP 3 and 48 hours. Prior to leptin
treatment, the cell culture medium was replaced with serum free medium for 4 hours.
To investigate the effect of PTP1B inhibition in hypothalamic cells, 10µM and 50µM
PTP1B inhibitor Lupeol (L5632, Sigma-Aldrich) and 5µM atypical antipsychotic
Olanzapine (O1141, Sigma-Aldrich) were dissolved in Dimethyl sulfoxide (DMSO),
then diluted in sterile water, and mixed with serum free cell culture medium. Cells were
exposed to 25µM PCP for 48 hours and replaced with serum free cell culture medium,
then lupeol, olanzapine and co-treatment were applied to cells for 24 hours individually.
To examine the influence of PTP1B inhibition on neurite synaptogenesis, 50µM lupeol
was administrated to primary hypothalamic neurons which have been treated by 25µM
PCP for 24 hours, and then co-incubated for another 24 hours. The DMSO
concentration was controlled below 0.5%.
Western blot analysis: Detailed protocols were described in our previous study (Yu et
al., 2013b), primary cultured hypothalamic neurons and mHypo neurons were washed
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with ice-cold PBS and lysed in NP-40 lysis buffer (FNN0021, Invitrogen) containing a
protease inhibitor cocktail, beta-glycerophosphate and phenylmethanesulfonyl fluoride
(PMSF) (Sigma- Aldrich). Protein concentrations were determined using the DC TM
Protein Assay kit (5000121, Bio-Rad Laboratories). Equal amounts of protein were
separated on 4-20% CriterionTM TGX

TM

Precast Gels (567-1095, Bio-Rad

Laboratories) using SDS-PAGE. Following electrophoresis (120 V for 1.5 h), the
proteins were transferred to polyvinylidene difluoride membranes (100 V for 1 hr).
Membranes were blocked in 5% bovine serum albumin (BSA) or 5% skim milk
depending on the primary antibodies used, followed by incubation with the primary
antibodies anti-PTP1B (SAB1306060, Sigma-Aldrich), anti-BDNF antibody (SC20981, Santa-Cruz), pNR2BTyr1472 (4208S, Cell Signalling Technology), NR2B (4207S,
Cell Signalling Technology), anti-pAktSer473 (D9E, Cell Signalling Technology), antiAkt (SC8312, Cell Signalling Technology), anti-pGSK3βSer9 (5B3, Cell Signalling
Technology), GSK3β (D75D3, Cell Signalling Technology), pJAK2Tyr1007/1008 (C80C3,
Cell

Signalling

Technology),

JAK2

(D2E12,

Cell

Signalling

Technology),

pSTAT3Tyr705 (D3A7, Cell Signalling Technology), STAT3 (79D7, Cell Signalling
Technology) and anti-actin (MAB1501, Millipore) in 1% BSA or 1% skim milk
overnight at 4C. Following washes (3×5 min) in Tris Buffered Saline+0.1% Tween 20,
membranes were incubated with respective secondary antibodies for 1 hr at 25C. Blots
were visualised using AmershamTM ECLTM Detection Reagents (RPN2106, Ge
Healthcare) and exposed in dark room. The bands corresponding to the proteins of
interest were scanned and analysed using the automatic imaging analysis system
Quantity One (Bio-Rad Laboratories). All quantitative analyses were normalised to
actin.
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Neuron Neuropeptide Y (NPY) detection: The mouse hypothalamic NPY/GFP
neurons (mHypoA-NPY/GFP neurons, CELLutions) were cultured in the 96-well plate
in the same incubation condition as mHypoA-59 neurons. 5µM olanzapine, 50µM
lupeol and co-treatment of olanzapine and lupeol were applied to neurons. After 6h
treatment,

discard

culture

medium

and

measure

neuron

NPY-bound

GFP

immunoactivity using FlexStation 3 (Molecular Devices). Wavelength of detection is
set from 488 nm to 510 nm, cutoff at 495 nm.
Statistical analysis: Data from the immunofluorescence imaging, RT-PCR analysis and
western blot were analysed using the SPSS 19 statistical package (SPSS, Chicago, IL).
One-way analysis of variance (ANOVA) was applied in all experiments followed by the
post-hoc Tukey-Kramer honestly significant difference (HSD) test.
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Figure Captions:
Fig.1: PTP1B expression stimulated by PCP in mouse hypothalamic A-59 (mHypo)
neurons and primary hypothalamic neurons. a): 25µM PCP for 3 hours treatment
significantly increased PTP1B expression in mHypo neurons. b): Both 1µM and 25µM
PCP for 48 hours increased PTP1B expression (+30% and +60%) (n=6). c and
d):PTP1B immunoreactivity was significantly increased in primary cultured
hypothalamic neurons treated with 25µM PCP for 48 hours (n=10). e): The level of
PTP1B mRNA level was significantly increased after 3 and 48 hours exposure to 25µM
PCP (n=6). Mean ± SEM, Scale bar =25µm, *p<0.05, **p<0.01.

Fig.2: PTP1B was induced by decreased pNR2B. a): PTP1B expression was
significantly increased by 50µM ifenprodil but not 5µM ifenprodil for 24h treatment (a)
(n=6). b): When ifenprodil treatment was prolonged to 48h, low dosage (5µM)
ifenprodil showed increased PTP1B expression as well (n=6).

c and d): NR2A

antagonist Peaqx did not change PTP1B expression when 5µM and 50µM dose were
used for 24 and 48 hours (n=6). e): Phosphorylated NR2B was significantly lower in the
Nrg1 KO hypothalamic neurons (n=6). f and g): PTP1B expression was significantly
higher in Nrg1 KO mice than wild type mice and 25µM PCP had no effect on PTP1B
expression in Nrg1 KO mice (n=10). Mean ± SEM, Scale bar =10µm, *p<0.05,
**p<0.01.

Fig.3: PCP reduced leptin induced elevation of BDNF, pJAK2 and pSTST3 in the
hypothalamic neurons. a): Leptin increased JAK2 and STAT3 phosphorylations,
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which were affected by PCP examined in both 3 and 48 hours. b and c): Leptin
increased BDNF protein (n=10) and mRNA (d) (n=6) level but were inhibited by PCP.
Mean ± SEM, Scale bar =25 µm, *p<0.05, **p<0.01.

Fig.4: PCP treatment reduced BDNF level and BDNF-mediated Akt/GSK3β
pathway, leading to decreased synaptophysin (SYN). PCP decreased BDNF
expression in mHypo neurons in 3 (a) and 48 (b) hours (n=6). c and d): PCP decreased
BDNF protein (n=10) and mRNA (e) (n=6) level in 3 and 48 hours in primary cultured
hypothalamic neurons. PCP reduced Akt and GSK3β phosphorylation in both 3 (f) and
48 (g) hours in mHypo neurons (n=6). h and i): PCP significantly decreased SYN level
in 48 hours (n=10). j): Both PCP 3h and 48h treatment reduced SYN mRNA (n=6).
Mean ± SEM, Scale bar =10µm, *p<0.05, **p<0.01.

Fig.5: Lupeol prevented PCP-induced changes in PTP1B, pJAK2, BDNF, pAkt,
pGSK3β and synaptophysin. a): PTP1B allosteric inhibitor lupeol reversed PCPinduced elevation of PTP1B, and down-regulation of pJAK2 and BDNF in
hypothalamic neurons (n=6). b): Lupeol reversed PCP-induced reduction of pAkt and
pGSK3β (n=6). c and d): Lupeol prevented SYN downregulation induced by PCP
(n=10). Mean ± SEM, Scale bar =10µm, *p<0.05, **p<0.01.

Fig.6: Lupeol improved olanzapine treatment effects and decreased olanzapineinduced NPY. a): Olanzapine could not inhibit PCP-induced increase of PTP1B which
was however prevented by a combined olanzapine and lupeol treatment (n=6). b and c):
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A combined olanzapine and lupeol treatment showed improved efficacy to increase
pJAK2, BDNF, pAkt and pGSK3β compared to olanzapine treatment (n=6). d):
Olanzapine treatment showed 1.4-fold increase of NPY which was inhibited with the
application of lupeol (n=10). Mean ± SEM, Scale bar =10µm, *p<0.05, **p<0.01,
***p<0.001.
Fig.7: PTP1B mediates NMDA receptor/NR2B antagonism induced impairment of
synaptogenesis. NR2B dysfunction induced by PCP or Nrg1 KO stimulated PTP1B.
Enhanced PTP1B directly reduced pJAK2, leading to impaired leptin signalling and
decreased pSTAT3 which further inhibited BDNF level, pAkt and pGSK3β expression
on synaptogenesis. Lupeol is a PTP1B allosteric inhibitor which prevented these
changes and restored altered BDNF and pAkt and pGSK3β pathway to improve
synaptogenesis.
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Fig.S2: PCP significantly increased PTP1B mRNA level but not TCPTP mRNA level. a:
RT-PCR analysis showed that neither PCP 3-h nor 48-h treatment increased TCPTP
mRNA expression (n=6). B): Both PCP 3-h and 48-h treatments increased PTP1B but
not TCPTP mRNA expression following leptin stimulation (n=6). Data are presented as
mean ± SEM, *p<0.05, **p<0.01.
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Fig.S3: a): 25 µM PCP for 48h inhibited NR2B phosphorylation. b): 5 µM Ifenprodil
for 48h reduced NR2B phosphorylation. Data are presented as mean ± SEM (n=6).
*p<0.05, **p<0.01.
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Chapter Four
A label-free and high-throughput separation of neuron and glial cells using an inertial
microfluidic platform

Reprinted from Biomicrofluidics, Copyright (2016), with permission from American
Institute of Physics (See Appendix A)
Available at: http://scitation.aip.org/content/aip/journal/bmf/10/3/10.1063/1.4949770
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Chapter Five
5.1 Overall Discussion
Increasing evidence has confirmed PTP1B as a promising therapeutic target for treating
obesity. However, PTP1B traditional inhibitors are targeting the PTP1B active site
which is very similar to other PTPs, causing off-target effects and reduced
bioavailability. Allosteric inhibition thus becomes a promising alternative strategy to
develop selective PTP1B inhibitors. Previous structural and biochemical studies have
unveiled the allosteric binding site, and allosteric inhibition aims to disturb PTP1B
conformational transition during catalysis and therefore inhibits PTP1B activity
(Wiesmann et al., 2004).
In Chapter 2, lupeol and lupane triterpenes including lupenone, betulin and betulinic
acid are identified as new PTP1B allosteric inhibitors. Using molecular docking, lupane
triterpenes were demonstrated to bind to the PTP1B allosteric site. The performance of
molecular dynamics simulations showed the stability of the protein-ligand complex and
elucidated the interactions between lupane triterpenes and the PTP1B binding site,
indicating the important role of helix 𝛼7 and several hydrophobic residues in the
binding mode. Moreover, the pentacyclic structure in lupane triterpenes is confirmed as
the main contributor to allosteric binding, while the different formation of hydrogen
bonds leads to variation of electrostatic forces, which explains the distinction between
binding affinity and inhibitory activity among lupane triterpenes. Further enzymatic
assays showed that lupane triterpenes specifically inhibited PTP1B over TCPTP. In
addition, molecular docking of lupane triterpenes targeting TCPTP was applied. It
appeared lupane triterpenes were not binding to TCPTP in the region which is
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equivalent to the allosteric site in PTP1B. Thus the less-conserved PTP1B allosteric site
is an ideal target for lupane triterpenes to inhibit PTP1B activity. Finally, lupane
triterpenes showed significant PTP1B activity inhibition effects in neuronal cells with
positive bioavailability and less toxicity.
Importantly, there was demonstrated relative consistency between computed data and
experimental results in this work. For example, results from binding free energy
calculations showed that betulinic acid had a better inhibitory effect than lupeol.
Betulinic acid is able to form stronger hydrogen bonding interactions than lupeol and
the other two lupane triterpenes, providing stronger electrostatic force, which is
consistent with the experimental IC50 data. Therefore, this computational modelling is
reliable to compare the inhibitory effects between lupane triterpenes derivatives. The
structural difference between lupeol and betulinic acid lies in the R2 group which
strongly enhance the inhibitory effect of betulinic acid. Considering that the non-polar
pentacyclic structure of lupane triterpenes is the premise for binding to the less polar
allosteric site, modification of the polar functional group is an alternative choice.
Currently all lupane triterpenes are difficult to dissolve in water which limits drug
administration, therefore further modification could be focused on increasing
hydrophilicity. However, such modifications need careful investigation since this will
affect their pharmacokinetic properties. As an important negative regulator modulating
food intake, body weight gain and energy homeostasis, PTP1B is an attractive drug
target for preventing and treating obesity and its associated metabolic syndromes
including diabetes. This study provides a reliable PTP1B allosteric inhibitor discovery
platform, with combined computational modelling and biological assays, to develop
new PTP1B allosteric inhibitors including lupane triterpenes derivatives with enhanced
potency, selectivity and bioavailability.
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Recent studies have revealed the role of PTP1B in blocking BDNF-mediated signalling
and causing impaired neurogenesis in several neurological diseases (Krishnan et al.,
2015). Given the prevalence of BDNF reduction in schizophrenia patients, it is crucial
to investigate whether PTP1B is involved in impaired neurogenesis in schizophrenia. In
Chapter 3, PTP1B level is significantly induced in two schizophrenia-like models, PCPtreated model and NRG1 KO mouse model, both well-established models to mimic the
schizophrenia symptoms in humans. PCP, as a well-recognized non-selective NMDAR
antagonist, binds equally to NR2A and NR2B subunits (Paoletti and Neyton, 2007). To
further investigate the mechanism of PCP induced PTP1B, NR2A specific antagonist
PEAQX and NR2B specific antagonist ifenprodil were tested to stimulate PTP1B
expression. Results showed that only ifenprodil treatment with reduced NR2B
phosphorylation was able to increase PTP1B level. Moreover, the reduction of NR2B
phosphorylation and enhanced PTP1B expression was also disclosed in Nrg1 KO mice
which supported our finding that NR2B downregulated PTP1B. On the other hand,
Nrg1-ErbB4 signalling is required for NR2B phosphorylation (Bjarnadottir et al., 2007).
A recent study has reported that PTP1B inhibits TrkB, a crucial regulator which
interacts with ErbB4 to modulate Nrg1-induced NR2B phosphorylation (Pandya and
Pillai, 2014), indicating that NR2B dephosphorylation induced PTP1B which further
inhibited Nrg1-induced NR2B phosphorylation as a negative feedback. Both NR2B
deficient and NRG1 gene mutation are important contributors to the risk of
schizophrenia (Stefansson et al., 2002, Bjarnadottir et al., 2007), and PTP1B appears to
be a crucial factor in the psychopathology.
Moreover, the reduction of BDNF and BDNF-mediated Akt/GSK3β signalling leads to
impaired neurogenesis and synaptogenesis, which has been demonstrated in
schizophrenia patients (Weickert et al., 2003, Weickert et al., 2005, Favalli et al., 2012)
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as well as PCP-treated models (Snigdha et al., 2011, Adachi et al., 2013, Katanuma et
al., 2014, Zhang et al., 2016). However the mechanism remains unclear. This study
proposes that PTP1B regulates the BDNF level and BDNF-mediated Akt/GSK3β
signalling in the PCP-treated model. PTP1B has been reported to inhibit TrkB, which is
the transmembrane receptor of BDNF (Ozek et al., 2014, Krishnan et al., 2015), and
modulates BDNF-mediated Akt/GSK3β signalling. In Chapter 3, elevated PTP1B
suppressed pAkt and pGSK3β, and inhibition of PTP1B restored Akt/GSK3β signalling
and downstream synaptogenesis. Therefore, PTP1B is able to block Akt/GSK3β
signalling and results in impaired neurogenesis and synaptogenesis. This study also
revealed that PTP1B directly modulates BDNF level through leptin-mediated
JAK2/STAT3 signalling. Leptin stimulates BDNF expression in the dendrites of
hypothalamic neurons (Liao et al., 2012), as well as BDNF mRNA in the hypothalamic
region (Komori et al., 2006). In Chapter 2, leptin signalling has been confirmed to be
inhibited by PCP-induced PTP1B, which directly dephosphorylated JAK2 and blocked
leptin-mediated JAK2/STAT3 signalling, leading to the BDNF reduction. Previous
studies have suggested that leptin exclusively improves NMDA receptor-regulated
synaptic transmission such as the induction of long-term potentiation (Shanley et al.,
2001, Harvey et al., 2005, Harvey, 2007), indicating that leptin signalling is capable of
improving the NMDA-mediated signalling pathway. The present study showed that
NMDA receptor antagonism stimulated PTP1B which affected hypothalamic leptin
signalling, indicating the reciprocal interactions between NMDA receptor and leptin
signalling pathways. Considering the important role of leptin signalling in controlling
food intake, weight gain and energy homeostasis, the disturbed leptin function in the
PCP-treated model may explain the prevalence of obesity in schizophrenia patients.
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Based on the results from Chapter 2, lupeol was identified as a PTP1B allosteric
inhibitor which inhibits PTP1B with potency and selectivity over TCPTP. It is worth
mentioning that in the PCP-treated model, only PTP1B was increased but not TCPTP,
suggesting PTP1B selective inhibition is required for treatment. Therefore, lupeol was
applied to the PCP-treated model with or without olanzapine treatment, to investigate
the co-treatment effect of PTP1B inhibition and olanzapine. Olanzapine showed no
effects on preventing PCP-induced overexpression of PTP1B and reduction of leptin
downstream JAK2 and BDNF although BDNF-mediated Akt/GSK3β signalling was
restored. However, lupeol inhibited PCP-induced PTP1B expression and the cotreatment of lupeol and olanzapine confirmed improved effects in reversing PCPinduced alterations including reduction of BDNF, Akt/GSK3β signalling, and decreased
synaptophysin, mainly due to the PTP1B inhibition-related restoration of JAK2/STAT3
signalling, which stimulated BDNF expression. Importantly, a recent study has shown
the interactions between olanzapine-induced weight gain and an elevated orexigenic
neurotransmitter, neuropeptide Y (NPY) mRNA level (Weston-Green et al., 2012). The
co-treatment of olanzapine and lupeol managed to inhibit the olanzapine-induced NPY
level. Therefore, co-treatment of PTP1B inhibitor, lupeol, with olanzapine may enhance
olanzapine’s treatment efficacy and prevent olanzapine-induced weight gain.
Interest in glia is rising due to increasing evidence supporting the important role of
dynamic neuron–glia in neurogenesis and synaptic formation. For example, astrocyte,
one type of glia, modulates multiple aspects of neuron growth and synaptic function
from development through to adulthood, including involvement in synapse formation,
as well as uptake and recycling of neurotransmitters. Recent studies also revealed
astrocytic dysfunction in several brain disorders including schizophrenia with
significant cognitive impairments. Astrocyte loss has been observed in the prefrontal
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cortex which triggered neuronal damage causing cognitive impairment in the animal
model (Lima et al., 2014). Consequently, astrocyte could have an as yet unexpected role
in the neuron-glia interactions in the diseased brain. An improved understanding of
astrocyte biology and function offers the potential for developing novel strategies to
treat neurological disorders. Despite the growing realization of the importance of the
neuron-glia relationship, we are still in the early stages of understanding the
physiological consequences of the bidirectional communication between neurons and
glia, mainly due to the difficulty in separating neurons and glia from the cell mixture in
brain tissue.
In Chapter 4, a high-throughput microfluidic platform based on an inertial microfluidic
technique was established to separate neurons and glial cells from dissected brain tissue
rapidly and continuously. The microfluidic platform was set up based on size-dependent
separation due to the significant variation of cell diameters between neurons and glia.
Larger-size cells collected from the middle outlet were characterised as neurons while
smaller cells collected from the aside outlet were determined as glia. Immunostaining
was applied to test the cell types and confirm the high separation effects. Collected cells
were then incubated for downstream experiments. This method provided highly
enriched and purified neurons and glia, compared to the traditional methods, in which
glial cells are mixed with neurons, and each well for incubation only contains a limited
numbers of cells of interest. Moreover, separated neurons were as healthy and
functional as unprocessed neurons, and there was no significant variation in the growth
and synaptogenesis of neurites caused by the inertial separation process.
Cell sorting has been broadly applied in biological studies, however live cell sorting
from tissue is still a challenge. Fluorescence-activated cell sorting (FACS) and
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magnetically-activated cell sorting (MACS) have been used for sorting cells. However,
these methods require cell labelling which is a time and labour consuming step, and
more importantly, application of antibodies to label cells will further interfere with the
immunochemistry analysis of target proteins of interest. Microfluidic technology has
been introduced to perform cell sorting studies. Dielectrophoresis (DEP)-based
microfluidic devices distinguish cells by their dielectric properties as a label-free
technique. However these devices normally run in a batch manner and with a very
limited throughput. Apart from DEP, another study has reported the application of
viscoelasticity-tuned hydrodynamic spreading to neural cell separation where the
microfluidic device works in a continuous and label free manner (Wu et al., 2008). Such
a device could achieve relative high viability of neural cells through separation.
However, the flow rate (20 µl/h) and the throughput (3 ×104 cells/h) are still not
satisfactory, and therefore need further improvement. This study applied a label-free
and high-throughput microfluidic device in which cells passed through the
microchannel in an inertial microchip at ~1 m/s with significantly improved throughput
of 1.188 ×107 cells/h. Although the current throughput rate is still lower than FACS, this
proposed device can be further amplified by parallelizing several microchannels to
increase throughput capability. Importantly, the present inertial microfluidic platform is
biocompatible, elastomeric, transparent and gas-permeable, suitable for cell incubation.
In future studies, this device will be designed to establish a multi-functional platform
combining separating, sorting, incubation and neurite outgrowth measurement, to
further investigate the neuron-glia interactions and proteins of interest. For example, a
recent study has found PTP1B in microglia contributing to neuroinflammation (Song et
al., 2016) and neuroinflammation is strongly linked to development of neurological
disorders including schizophrenia (Meyer, 2013). Therefore, it is of great interest to
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discover the role of PTP1B in glial cells regulating neurite outgrowth, synaptic
formation and neurotransmitters function in future studies, with application of the
inertial microfluidic platform.

5.2 Conclusion
PTP1B has been reported to impair BDNF-mediated signalling and then inhibit neurite
outgrowth and synaptic formation. Moreover, PTP1B blocks leptin signalling which is
known to increase BDNF and promote neurite outgrowth. Therefore PTP1B is a
potential drug target to reverse abnormality of BDNF-mediated neurogenesis in
neurological disorders. In this study, lupane triterpenes, a cluster of natural products,
were determined as novel PTP1B allosteric inhibitors which inhibit PTP1B with strong
potency and selectivity. Lupane triterpenes inhibit psychotomimetic drug-induced
PTP1B and reverse PTP1B-induced BDNF reduction and neurogenesis impairment,
demonstrating that lupane triterpenes are potential drug candidates for PTP1B inhibition
and PTP1B-related neurological disorders.
In the present study, lupeol and other members of lupane triterpenes were demonstrated
as PTP1B allosteric inhibitors. With the application of molecular modelling and
biological assay, lupeol was revealed to target the PTP1B allosteric binding site to
inhibit PTP1B with selectivity and potency. Through the investigation of lupeol
structural properties, further structural modification was determined to discover a series
of lupeol derivatives.
PTP1B is identified as a new factor contributing to the psychopathology in
schizophrenia-like models. PTP1B was found significantly increased during the
psychotomimetic drug (phencyclidine) treatment, resulting in the decrese of leptin
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signalling, reduction of BDNF level, attenuation of the BDNF-mediated Akt/GSK3β
pathway and neurogenesis, suggesting PTP1B as a new drug target.
Furthermore, the natural triterpene lupeol was applied to prevent PCP-induced PTP1B
expression.

Lupeol

managed

to

reduce

PTP1B and

reversed

PCP-induced

schizophrenia-like alterations. Importantly, the combined treatment of lupeol and
atypical antipsychotic, olanzapine, showed improved treatment efficacy and reduced
side effects compared to individual olanzapine application, implicating PTP1B
inhibition as a potential treatment strategy.
Finally, to investigate the role of PTP1B in specific cell types of neurons and glia in
future studies, an inertial microfluidic biochip was introduced to separate neurons and
glia from mouse brain tissue for primary cell culture. This microfluidic platform was a
high through-put device, able to separate neurons and glia with efficiency and purity,
and there was no damage to cell viability and biological functions during the process.
In conclusion, this PhD project determined natural compounds lupane triterpenes as new
PTP1B allosteric inhibitors which inhibit PTP1B with high potency and selectivity.
PTP1B was further confirmed as contributing to BDNF reduction and neurogenesis
impairment in schizophrenia-like models, indicating PTP1B as a potential drug target.
Application of lupane triterpene significantly improved therapeutic efficacy and
prevented the side effects induced by antipsychotics. Finally, development of the
microfluidic microchip will improve investigation of PTP1B in specific cell types in
future studies.

5.3 Recommendations for Future Research
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1. Further characterise the interactions between lupane triterpenes and PTP1B allosteric
site. Experimental methods including NMR and mutant protein purification
technologies will be applied to determine the crucial amino acids in PTP1B which
contribute to the allosteric binding mode.
2. Chemical modifications of lupeol based on results and discussions in Chapter 2 and
future NMR data. Apply computer-aid drug design to develop novel lupeol derivatives
targeting PTP1B allosteric site with improved potency, selectivity and bioavailability.
3. Application of new lupeol derivatives on neural cell cultures to improve neurite
outgrowth, synaptic function and relative signalling pathway.
4. Animal models will be applied in future studies to test the improved behaviour and
cognition with the treatment of lupeol derivatives.
5. Combination of lupeol derivatives and antipsychotic olanzapine will be administrated
to animal models to demonstrate improved treatment efficacy with reduced side effects
such as body weight gain.
6. Microfluidics-based cell culture system will be established using new biocompatible
materials and high-resolution fabrication technologies, to separate neurons and glia with
purity and viability from brain sections.
7. With the new established microfluidic system, PTP1B in microglia will be examined
to determine its contributions to neuroinflammation. PTP1B in astrocyte will be
investigated to reveal its role contributing to impaired neurite outgrowth and
neurogenesis in neurological disorders.
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8. The microfluidic system could be further modified to establish neuron-glia co-culture
system, to investigate the neuron-glia interactions in neurological disorders and reveal
the role of PTP1B involved.
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